Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Liver Diseases

  Free Subscription


Articles published in J Hepatol

Retrieve available abstracts of 471 articles:
HTML format



Single Articles


    November 2021
  1. CABIBBO G, Singal AG
    The quest for precision oncology with immune checkpoint inhibitors and hepatocellular carcinoma.
    J Hepatol. 2021 Nov 26. pii: S0168-8278(21)02226.
    PubMed    


  2. LIU Y, Zhuo S, Zhou Y, Ma L, et al
    Yap-Sox9 signaling determines hepatocyte plasticity and lineage-specific hepatocarcinogenesis.
    J Hepatol. 2021 Nov 15. pii: S0168-8278(21)02182.
    PubMed     Abstract available


  3. D'AVOLA D, Granito A, de la Torre-Alaez M, Piscaglia F, et al
    The importance of liver functional reserve in the non-surgical treatment of Hepatocellular Carcinoma.
    J Hepatol. 2021 Nov 15. pii: S0168-8278(21)02185.
    PubMed     Abstract available


  4. SABOO K, Petrakov NV, Shamsaddini A, Fagan A, et al
    Stool microbiota are superior to saliva in distinguishing cirrhosis and hepatic encephalopathy using machine learning.
    J Hepatol. 2021 Nov 15. pii: S0168-8278(21)02183.
    PubMed     Abstract available


  5. DING GY, Ma JQ, Yun JP, Chen X, et al
    Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma.
    J Hepatol. 2021 Nov 15. pii: S0168-8278(21)02178.
    PubMed     Abstract available


  6. TANTAI X, Liu Y, Yeo YH, Praktiknjo M, et al
    Effect of sarcopenia on survival in patients with cirrhosis: A systematic review and meta-analysis.
    J Hepatol. 2021 Nov 13. pii: S0168-8278(21)02174.
    PubMed     Abstract available


  7. HUO TI, Liao JI, Ho SY
    Prognostic prediction for patients with hepatocellular carcinoma receiving immunotherapy: Are we there yet?
    J Hepatol. 2021 Nov 12. pii: S0168-8278(21)02176.
    PubMed    


  8. XU X, Nan Y
    Reply to: Correspondence on "The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease".
    J Hepatol. 2021 Nov 11. pii: S0168-8278(21)02170.
    PubMed    


  9. PAVLIDES M, Francis S, Barnes E
    Abbreviated MRI to screen for HCC in patients with cirrhosis. A step forward but a long road ahead.
    J Hepatol. 2021 Nov 8. pii: S0168-8278(21)02169.
    PubMed    


  10. SANGRO B, Bruix J, Chan SL, Galle PR, et al
    Immunotherapy for patients with hepatocellular carcinoma and chronic viral infections.
    J Hepatol. 2021 Nov 1. pii: S0168-8278(21)02162.
    PubMed    


  11. HAN Y, Black S, Gong Z, Chen Z, et al
    Membrane-delimited signaling and cytosolic action of MG53 preserve hepatocyte integrity during drug-induced liver injury.
    J Hepatol. 2021 Nov 1. pii: S0168-8278(21)02154.
    PubMed     Abstract available


    October 2021
  12. CHAO X, Wang S, Fulte S, Ma X, et al
    Hepatocytic p62 suppresses ductular reaction and tumorigenesis in mouse livers with mTORC1 activation and defective autophagy.
    J Hepatol. 2021 Oct 25. pii: S0168-8278(21)02151.
    PubMed     Abstract available


  13. LOGLIO A, Ferenci P, Uceda Renteria SC, Tham CYL, et al
    Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis.
    J Hepatol. 2021 Oct 23. pii: S0168-8278(21)02119.
    PubMed     Abstract available


  14. LAN T, Hu Y, Hu F, Li H, et al
    Hepatocyte glutathione S-transferase mu 2 prevents non-alcoholic steatohepatitis by suppressing ASK1 signaling.
    J Hepatol. 2021 Oct 14. pii: S0168-8278(21)02105.
    PubMed     Abstract available


  15. WHITFIELD JB, Schwantes-An TH, Darlay R, Aithal GP, et al
    A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers.
    J Hepatol. 2021 Oct 13. pii: S0168-8278(21)02111.
    PubMed     Abstract available


  16. QING J, Ren Y, Zhang Y, Yan M, et al
    Dopamine receptor D2 antagonization normalizes profibrotic macrophage-endothelial crosstalk in non-alcoholic steatohepatitis.
    J Hepatol. 2021 Oct 11. pii: S0168-8278(21)02097.
    PubMed     Abstract available


  17. SCHEINER B, Pomej K, Kirstein MM, Hucke F, et al
    Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.
    J Hepatol. 2021 Oct 11. pii: S0168-8278(21)02100.
    PubMed     Abstract available


  18. SEN P, Qadri S, Luukkonen PK, Ragnarsdottir O, et al
    Exposure to environmental contaminants is associated with altered hepatic lipid metabolism in non-alcoholic fatty liver disease.
    J Hepatol. 2021 Oct 7. pii: S0168-8278(21)02104.
    PubMed     Abstract available


  19. PINYOL R, Torrecilla S, Wang H, Montironi C, et al
    Corrigendum to 'Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis' [J Hepatol 75 (2021) 865-878].
    J Hepatol. 2021 Oct 6. pii: S0168-8278(21)02044.
    PubMed    


  20. BEAUFRERE A, Caruso S, Calderaro J, Pote N, et al
    Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies.
    J Hepatol. 2021 Oct 5. pii: S0168-8278(21)02099.
    PubMed     Abstract available


  21. KIM HY, Lampertico P, Nam JY, Lee HC, et al
    An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B.
    J Hepatol. 2021 Oct 1. pii: S0168-8278(21)02087.
    PubMed     Abstract available


  22. BAFFY G, Bosch J
    Overlooked subclinical portal hypertension in non-cirrhotic NAFLD: Is it real and how to measure it?
    J Hepatol. 2021 Oct 1. pii: S0168-8278(21)02090.
    PubMed     Abstract available


  23. WONG F, Piano S, Angeli P
    Reply to: Correspondence on "Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure".
    J Hepatol. 2021;75:1010-1012.
    PubMed    


  24. FENG MW, Hanley KL, Feng GS
    Androgen receptor, neovascularization and liver cancer metastasis.
    J Hepatol. 2021;75:768-769.
    PubMed    


  25. LIN S, Agarwal B, Kumar R, Jalan R, et al
    Defining the prognosis of critically ill patients with alcohol-related liver disease.
    J Hepatol. 2021;75:986-987.
    PubMed    


  26. FISCHER P, Stefanescu H, Hategan R, Procopet B, et al
    Bacterial infection-related acute-on-chronic liver failure: The standpoint matters!
    J Hepatol. 2021;75:1009-1010.
    PubMed    


    September 2021
  27. GIABICANI M, Le Menestrel A, Roux O, Rautou PE, et al
    Focus on the decisions to forego life-sustaining therapies during ICU stay of patients with cirrhosis and COVID-19: a case control study from the prospective COVID-ICU database.
    J Hepatol. 2021 Sep 30. pii: S0168-8278(21)02080.
    PubMed    


  28. HSIEH J, Molusky MM, McCabe KM, Fotakis P, et al
    TTC39B destabilizes retinoblastoma protein promoting hepatic lipogenesis in a sex-specific fashion.
    J Hepatol. 2021 Sep 30. pii: S0168-8278(21)02083.
    PubMed     Abstract available


  29. GRONEBERG M, Hoenow S, Marggraff C, Fehling H, et al
    HIF-1alpha modulates sex-specific Th17/Treg responses during hepatic amoebiasis.
    J Hepatol. 2021 Sep 29. pii: S0168-8278(21)02082.
    PubMed     Abstract available


  30. D'AMBROSIO R, Degasperi E, Anolli MP, Fanetti I, et al
    Incidence of liver and non-liver-related outcomes in patients with HCV-cirrhosis after SVR.
    J Hepatol. 2021 Sep 27. pii: S0168-8278(21)02043.
    PubMed     Abstract available


  31. CHOI WM, Yip TC, Lim YS, Wong GL, et al
    Methodological Challenges in Meta-Analysis to Assess the Risk of Hepatocellular Carcinoma Across Chronic Hepatitis B Treatments.
    J Hepatol. 2021 Sep 27. pii: S0168-8278(21)02079.
    PubMed     Abstract available


  32. PATEL V, Lee S, McPhail M, Da Silva K, et al
    Rifaximin reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial.
    J Hepatol. 2021 Sep 24. pii: S0168-8278(21)02040.
    PubMed     Abstract available


  33. KIM HS, Yu X, Kramer J, Thrift AP, et al
    Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States.
    J Hepatol. 2021 Sep 23. pii: S0168-8278(21)02039.
    PubMed     Abstract available


  34. JUANOLA A, Graupera I, Elia C, Piano S, et al
    Urinary L-FABP is a promising prognostic biomarker of ACLF and mortality in patients with decompensated cirrhosis.
    J Hepatol. 2021 Sep 13. pii: S0168-8278(21)02029.
    PubMed     Abstract available


  35. CHEN Q, Wang H, Li Z, Li F, et al
    Circular RNA ACTN4 promotes intrahepatic cholangiocarcinoma progression by recruiting YBX1 to initiate FZD7 transcription.
    J Hepatol. 2021 Sep 9. pii: S0168-8278(21)02025.
    PubMed     Abstract available


  36. DAI CY, Yeh ML, Yu ML
    An EASL position paper for systemic treatment of hepatocellular carcinoma: Go forward courageously.
    J Hepatol. 2021 Sep 4. pii: S0168-8278(21)02021.
    PubMed    


  37. DING ZY, Li GX, Shu C, Yin P, et al
    Reply to: Comments on "Association of liver abnormalities with in-hospital mortality in patients with COVID-19".
    J Hepatol. 2021;75:742-744.
    PubMed    


  38. LUO MS, Huang GJ
    Letter regarding "Association of liver abnormalities with in-hospital mortality in patients with COVID-19".
    J Hepatol. 2021;75:737-739.
    PubMed    


  39. SINGH A, Premkumar M, Singh V
    Liver injury in COVID-19 - The culprit may not be COVID-19!
    J Hepatol. 2021;75:739-740.
    PubMed    


  40. MCCONNELL MJ, Kawaguchi N, Kondo R, Sonzogni A, et al
    Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy.
    J Hepatol. 2021;75:647-658.
    PubMed     Abstract available


  41. WANG Q, Bai W, Han G
    Freiburg index of post-TIPS survival: The first score for individual prediction and a complementary tool for risk stratification.
    J Hepatol. 2021;75:747-749.
    PubMed    


  42. BETTINGER D, Thimme R, Schultheiss M
    Reply to: Correspondence on "Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival".
    J Hepatol. 2021;75:749-750.
    PubMed    


  43. PAPATHEODORIDI M, Pinzani M, Tsochatzis E
    Reply to: "Do we need to re-define the Baveno VI elastography criteria for compensated advanced chronic liver disease (cACLD)?"
    J Hepatol. 2021;75:752-753.
    PubMed    


  44. PARK H, Yoon EL, Cho S, Nah EH, et al
    Do we need a new cut-off for FIB-4 in the metabolic dysfunction-associated fatty liver disease era?
    J Hepatol. 2021;75:725-726.
    PubMed    


  45. MA L, Craig AJ, Heinrich S
    Hypoxia is a key regulator in liver cancer progression.
    J Hepatol. 2021;75:736-737.
    PubMed    


  46. KRAGLUND F, Gantzel RH, Jepsen P, Aagaard NK, et al
    External validation of the Freiburg index of post-TIPS survival.
    J Hepatol. 2021;75:746-747.
    PubMed    


  47. GENESCA J, Abraldes JG, Bosch J
    Do we need to re-define the Baveno VI elastography criteria for compensated advanced chronic liver disease (cACLD)?
    J Hepatol. 2021;75:750-752.
    PubMed    


    August 2021
  48. WANG H, Zhang S, Zhang Y, Jia J, et al
    TAZ is indispensable for c-MYC-induced hepatocarcinogenesis.
    J Hepatol. 2021 Aug 28. pii: S0168-8278(21)02016.
    PubMed     Abstract available


  49. DAI CY, Chuang WL, Yu ML
    A prospective study in predicting portal thrombosis in cirrhosis: Some Issues.
    J Hepatol. 2021 Aug 27. pii: S0168-8278(21)02010.
    PubMed    


  50. RICKE J, Schinner R, Seidensticker M, Gasbarrini A, et al
    Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma.
    J Hepatol. 2021 Aug 26. pii: S0168-8278(21)02003.
    PubMed     Abstract available


  51. BLOOM P, Tapper EB, Young VB, Lok AS, et al
    Microbiome Therapeutics for Hepatic Encephalopathy.
    J Hepatol. 2021 Aug 25. pii: S0168-8278(21)01998.
    PubMed     Abstract available


  52. WANG H, Zhang H, Wang Y, Brown ZJ, et al
    Regulatory T cell and neutrophil extracellular trap interaction contributes to carcinogenesis in non-alcoholic steatohepatitis.
    J Hepatol. 2021 Aug 4. pii: S0168-8278(21)01962.
    PubMed     Abstract available


  53. WANG J, Hou Z, Liu J, Gu Y, et al
    Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study.
    J Hepatol. 2021;75:439-441.
    PubMed     Abstract available


    July 2021
  54. TORGERSEN J, Newcomb CW, Carbonari DM, Rentsch CT, et al
    Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation.
    J Hepatol. 2021 Jul 29. pii: S0168-8278(21)01950.
    PubMed     Abstract available


  55. TURON F, Driever EG, Baiges A, Cerda E, et al
    Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors.
    J Hepatol. 2021 Jul 29. pii: S0168-8278(21)01946.
    PubMed     Abstract available


  56. CARPINO G, Cardinale V, Di Giamberardino A, Overi D, et al
    Thrombospondin 1 and 2 along with PEDF inhibit angiogenesis and promote lymphangiogenesis in intrahepatic cholangiocarcinoma.
    J Hepatol. 2021 Jul 27. pii: S0168-8278(21)01947.
    PubMed     Abstract available


  57. GALLE PR, Abou-Alfa G
    Decision making in systemic therapy of hepatocellular carcinoma: should we pay attention to disease etiology?
    J Hepatol. 2021 Jul 23. pii: S0168-8278(21)01913.
    PubMed    


  58. SCHULTALBERS M, Grote-Koska D, Cornberg M, Schmidt JJ, et al
    Plasma and ascites pharmacokinetic of meropenem in patients with decompensated liver cirrhosis and spontaneous bacterial peritonitis.
    J Hepatol. 2021 Jul 23. pii: S0168-8278(21)01914.
    PubMed    


  59. BRISSOT P, Loreal O
    Hemochromatoses.
    J Hepatol. 2021 Jul 11. pii: S0168-8278(21)00226.
    PubMed    


  60. BRUIX J, Chan SL, Galle PR, Rimassa L, et al
    Systemic treatment of hepatocellular carcinoma. An EASL position paper.
    J Hepatol. 2021 Jul 10. pii: S0168-8278(21)01903.
    PubMed     Abstract available


  61. VAQUERO J, Keitel V
    Deciphering FAK in intrahepatic cholangiocarcinoma: a novel therapeutic target?
    J Hepatol. 2021 Jul 9. pii: S0168-8278(21)01902.
    PubMed    


  62. CLARIA J, Curto A, Moreau R, Colsch B, et al
    Untargeted lipidomics uncovers lipid signatures distinguishing severe versus moderate forms of acutely decompensated cirrhosis.
    J Hepatol. 2021 Jul 7. pii: S0168-8278(21)01895.
    PubMed     Abstract available


  63. ZHU C, Boucheron N, Muller AC, Majek P, et al
    24-NorUrsodeoxycholic acid reshapes immunometabolism in CD8(+) T-cells and alleviates hepatic inflammation.
    J Hepatol. 2021 Jul 6. pii: S0168-8278(21)01886.
    PubMed     Abstract available


  64. BETTINGER D, Thimme R, Schultheiss M
    Reply: TIPS and liver transplantation should always be discussed together.
    J Hepatol. 2021 Jul 6. pii: S0168-8278(21)01891.
    PubMed    


  65. SLADKY VC, Eichin F, Reiberger T, Villunger A, et al
    Polyploidy control in hepatic health and disease.
    J Hepatol. 2021 Jul 3. pii: S0168-8278(21)01879.
    PubMed     Abstract available


  66. ALVARADO-TAPIAS E, Vilades D, Brujats A, Villanueva C, et al
    Reply letter to correspondence entitled: "Non-selective beta blockers and mortality in decompensated Cirrhosis: Is Cirrhotic Cardiomyopathy the missing link?"
    J Hepatol. 2021 Jul 2. pii: S0168-8278(21)01846.
    PubMed    


  67. VAN DER MERWE S, Chokshi S, Bernsmeier C, Albillos A, et al
    The multifactorial mechanisms of bacterial infection in decompensated cirrhosis.
    J Hepatol. 2021;75 Suppl 1:S82-S100.
    PubMed     Abstract available


  68. TREBICKA J, Macnaughtan J, Schnabl B, Shawcross DL, et al
    The microbiota in cirrhosis and its role in hepatic decompensation.
    J Hepatol. 2021;75 Suppl 1:S67-S81.
    PubMed     Abstract available


  69. ENGELMANN C, Claria J, Szabo G, Bosch J, et al
    Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction.
    J Hepatol. 2021;75 Suppl 1:S49-S66.
    PubMed     Abstract available


  70. JEPSEN P, Younossi ZM
    The global burden of cirrhosis: A review of disability-adjusted life-years lost and unmet needs.
    J Hepatol. 2021;75 Suppl 1:S3-S13.
    PubMed     Abstract available


  71. TANDON P, Montano-Loza AJ, Lai JC, Dasarathy S, et al
    Sarcopenia and frailty in decompensated cirrhosis.
    J Hepatol. 2021;75 Suppl 1:S147-S162.
    PubMed     Abstract available


  72. JALAN R, D'Amico G, Trebicka J, Moreau R, et al
    New clinical and pathophysiological perspectives defining the trajectory of cirrhosis.
    J Hepatol. 2021;75 Suppl 1:S14-S26.
    PubMed     Abstract available


  73. GARCIA-PAGAN JC, Francoz C, Montagnese S, Senzolo M, et al
    Management of the major complications of cirrhosis: Beyond guidelines.
    J Hepatol. 2021;75 Suppl 1:S135-S146.
    PubMed     Abstract available


  74. CARACENI P, Abraldes JG, Gines P, Newsome PN, et al
    The search for disease-modifying agents in decompensated cirrhosis: From drug repurposing to drug discovery.
    J Hepatol. 2021;75 Suppl 1:S118-S134.
    PubMed     Abstract available


  75. FERNANDEZ J, Piano S, Bartoletti M, Wey EQ, et al
    Management of bacterial and fungal infections in cirrhosis: The MDRO challenge.
    J Hepatol. 2021;75 Suppl 1:S101-S117.
    PubMed     Abstract available


  76. JALAN R, Szabo G
    New concepts and perspectives in decompensated cirrhosis.
    J Hepatol. 2021;75 Suppl 1:S1-S2.
    PubMed    


  77. KREMOSER C
    FXR agonists for NASH: How are they different and what difference do they make?
    J Hepatol. 2021;75:12-15.
    PubMed    


  78. LIU Y, Xu N, Ji H
    Reply to: "Myofibroblast YAP/TAZ is dispensable for liver fibrosis in mice".
    J Hepatol. 2021;75:241-243.
    PubMed    


  79. BOSCH J
    Reply to: "Achieving an effective pressure reduction after TIPS: The need for a new target".
    J Hepatol. 2021;75:248-249.
    PubMed    


  80. STAUBER RE, Scharnagl H, Marsche G
    Reply to: "Prognostic value of HDL-related biomarkers in patients with HBV-related ACLF".
    J Hepatol. 2021;75:245-246.
    PubMed    


  81. SIMBRUNNER B, Costa D, Reiberger T
    Reply to: "Presepsin as a biomarker of inflammation and prognosis in decompensated liver disease".
    J Hepatol. 2021;75:234-236.
    PubMed    


  82. XU L, Wettschureck N, Bai Y, Yuan Z, et al
    Myofibroblast YAP/TAZ is dispensable for liver fibrosis in mice.
    J Hepatol. 2021;75:238-241.
    PubMed    


  83. WEN X, Tong J, Yao M, Hu J, et al
    Prognostic value of HDL-related biomarkers in patients with HBV-related ACLF.
    J Hepatol. 2021;75:243-245.
    PubMed    


  84. WANG X, Luo X, Yang L
    Achieving an effective pressure reduction after TIPS: The need for a new target.
    J Hepatol. 2021;75:246-248.
    PubMed    


  85. FERRARESE A, Plebani M, Frigo AC, Burra P, et al
    Presepsin as a biomarker of inflammation and prognosis in decompensated liver disease.
    J Hepatol. 2021;75:232-234.
    PubMed    


    June 2021
  86. MA L, Wang L, Khatib SA, Chang CW, et al
    Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    J Hepatol. 2021 Jun 30. pii: S0168-8278(21)01848.
    PubMed     Abstract available


  87. VITHAYATHIL M, Bridegwater J, Khan SA
    Medical therapies for intra-hepatic cholangiocarcinoma.
    J Hepatol. 2021 Jun 29. pii: S0168-8278(21)00238.
    PubMed    


  88. QUITT O, Luo S, Meyer M, Xie Z, et al
    T-cell engager antibodies enable T cells to control HBV infection and to target HBsAg-positive hepatoma in mice.
    J Hepatol. 2021 Jun 22. pii: S0168-8278(21)00443.
    PubMed     Abstract available


  89. D'AMICO G, Bernardi M, Angeli P
    TOWARDS A NEW DEFINITION OF DECOMPENSATED CIRRHOSIS.
    J Hepatol. 2021 Jun 19. pii: S0168-8278(21)00438.
    PubMed     Abstract available


  90. BOU SALEH M, Louvet A, Ntandja-Wandji LC, Boleslawski E, et al
    Loss of hepatocyte identity following aberrant YAP activation: a key mechanism in alcoholic hepatitis.
    J Hepatol. 2021 Jun 12. pii: S0168-8278(21)00416.
    PubMed     Abstract available


  91. GEIDL-FLUECK B, Gerber PA
    Reply to Comments on "Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis - A randomized controlled trial".
    J Hepatol. 2021 Jun 12. pii: S0168-8278(21)00418.
    PubMed    


  92. SELLAU J, Groneberg M, Hoenow S, Lotter H, et al
    The underlying cellular immune pathology of Entamoeba histolytica-induced hepatic amoebiasis.
    J Hepatol. 2021 Jun 11. pii: S0168-8278(21)00221.
    PubMed    


  93. WU J, Li H, Xu Z, Ran L, et al
    Population-specific cut-off points of fatty liver index for the diagnosis of hepatic steatosis.
    J Hepatol. 2021 Jun 9. pii: S0168-8278(21)00413.
    PubMed    


  94. CORPECHOT C
    Reply to: "Chronic fatigue should not be overlooked in primary biliary cholangitis".
    J Hepatol. 2021 Jun 6. pii: S0168-8278(21)00404.
    PubMed    


  95. FLEMMING JA, Velez MP
    The ART of medicine: Counselling women with liver disease about assisted reproductive technology.
    J Hepatol. 2021;74:1283-1285.
    PubMed    


  96. KUMAR R, Jalan R
    Reply to: "Failure to control variceal bleeding: Definition matters".
    J Hepatol. 2021;74:1492-1493.
    PubMed    


  97. BAIGES A, Bureau C, Garcia-Pagan JC
    Failure to control variceal bleeding: Definition matters.
    J Hepatol. 2021;74:1491-1492.
    PubMed    


    May 2021
  98. KOLAMUNNAGE-DONA R, Berhane S, Potts H, Williams EH, et al
    Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma.
    J Hepatol. 2021 May 27. pii: S0168-8278(21)00350.
    PubMed     Abstract available


  99. RUDLER M, Savier E, Alioua I, Sultanik P, et al
    TIPS and liver transplantation should always be discussed together.
    J Hepatol. 2021 May 26. pii: S0168-8278(21)00347.
    PubMed    


  100. BAUMERT TF
    "We can and should do better" - an interview with the 2020 Nobel prize laureates who revolutionized hepatology.
    J Hepatol. 2021 May 25. pii: S0168-8278(21)00312.
    PubMed    


  101. CORNBERG M, Eberhardt CS
    Protected or not protected, that is the question - First data on COVID-19 vaccine responses in patients with NAFLD and liver transplant recipients.
    J Hepatol. 2021 May 25. pii: S0168-8278(21)00342.
    PubMed    


  102. WANG H, Wen B, Chen J
    "Small esophageal varices in compensated cirrhosis patients: to treat or not to treat?" -Reply.
    J Hepatol. 2021 May 18. pii: S0168-8278(21)00335.
    PubMed    


  103. NAN Y, An J, Bao J, Chen H, et al
    The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease.
    J Hepatol. 2021 May 18. pii: S0168-8278(21)00332.
    PubMed     Abstract available


  104. ZHOU HC, Liu CX, Pan WD, Shang LR, et al
    Dual and opposing roles of the androgen receptor in VETC-dependent and invasion-dependent metastasis of hepatocellular carcinoma.
    J Hepatol. 2021 May 15. pii: S0168-8278(21)00331.
    PubMed     Abstract available


  105. PINYOL R, Torrecilla S, Wang H, Montironi C, et al
    Molecular characterization of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis.
    J Hepatol. 2021 May 13. pii: S0168-8278(21)00326.
    PubMed     Abstract available


  106. TRAMPERT DC, van de Graaf SFJ, Jongejan A, Oude Elferink RPJ, et al
    Erratum to: "Hepatobiliary acid-base homeostasis: Insights from analogous secretory epithelia" (J Hepatol 2021; 74: 428-441).
    J Hepatol. 2021 May 12. pii: S0168-8278(21)00330.
    PubMed    


  107. KUDO M, Matilla A, Santoro A, Melero I, et al
    CheckMate 040 Cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.
    J Hepatol. 2021 May 12. pii: S0168-8278(21)00313.
    PubMed     Abstract available


  108. ROMBAUT M, Boeckmans J, Rodrigues RM, van Grunsven LA, et al
    Direct reprogramming of somatic cells into induced hepatocytes: cracking the Enigma code.
    J Hepatol. 2021 May 11. pii: S0168-8278(21)00314.
    PubMed     Abstract available


  109. YEO YH, Hwang J, Jeong D, Dang N, et al
    Surveillance of patients with cirrhosis remains suboptimal in the United States.
    J Hepatol. 2021 May 6. pii: S0168-8278(21)00307.
    PubMed     Abstract available


  110. HYUN J, Al Abo M, Dutta RK, Oh SH, et al
    Dysregulation of the ESRP2-NF2-YAP/TAZ axis promotes hepatobiliary carcinogenesis in non-alcoholic fatty liver disease.
    J Hepatol. 2021 May 5. pii: S0168-8278(21)00298.
    PubMed     Abstract available


  111. CABRE N, Luciano-Mateo F, Chapski DJ, Baiges-Gaya G, et al
    Glutaminolysis-induced mTORC1 activation drives non-alcoholic steatohepatitis progression.
    J Hepatol. 2021 May 4. pii: S0168-8278(21)00302.
    PubMed     Abstract available


  112. JOHNSON PJ
    In search of an evidence base for HCC surveillance: Purity or pragmatism?
    J Hepatol. 2021;74:1025-1027.
    PubMed    


  113. ARROYO V, Fernandez J, Moreau R
    Reply to: "Systemic inflammation and disorders of hemostasis in the AD-ACLF syndrome".
    J Hepatol. 2021;74:1265-1267.
    PubMed    


  114. COENRAAD MJ, Artru F
    Amino acids in acute-on-chronic liver failure: Another piece of the puzzle?
    J Hepatol. 2021;74:1015-1017.
    PubMed    


  115. ESLAM M, George J
    MAFLD: Now is the time to capitalize on the momentum.
    J Hepatol. 2021;74:1262-1263.
    PubMed    


  116. FOUAD Y, Gomaa A, Semida N, Ghany WA, et al
    Change from NAFLD to MAFLD increases the awareness of fatty liver disease in primary care physicians and specialists.
    J Hepatol. 2021;74:1254-1256.
    PubMed    


  117. ALEM SA, Gaber Y, Abdalla M, Said E, et al
    Capturing patient experience: A qualitative study of change from NAFLD to MAFLD real-time feedback.
    J Hepatol. 2021;74:1261-1262.
    PubMed    


  118. KASPER P, Martin A, Lang S, Demir M, et al
    Hypertension in NAFLD: An uncontrolled burden.
    J Hepatol. 2021;74:1258-1260.
    PubMed    


  119. SPEARMAN CW, Desalegn H, Ocama P, Awuku YA, et al
    The sub-Saharan Africa position statement on the redefinition of fatty liver disease: From NAFLD to MAFLD.
    J Hepatol. 2021;74:1256-1258.
    PubMed    


  120. ZHANG Y, Lu Z, Zeng W, Zhao J, et al
    Two sides of NNMT in alcoholic and non-alcoholic fatty liver development.
    J Hepatol. 2021;74:1250-1253.
    PubMed    


    April 2021
  121. IZZY M, Lin G, Watt KD
    Non-selective beta blockers and mortality in decompensated Cirrhosis: Is Cirrhotic Cardiomyopathy the missing link?
    J Hepatol. 2021 Apr 28. pii: S0168-8278(21)00260.
    PubMed    


  122. SENZOLO M, Garcia-Tsao G, Garcia-Pagan JC
    Current knowledge and management of portal vein thrombosis in cirrhosis.
    J Hepatol. 2021 Apr 27. pii: S0168-8278(21)00265.
    PubMed     Abstract available


  123. BETTINGER D, Kloeckner R, Boettler T, Thimme R, et al
    Reply: Freiburg index of post-TIPS survival (FIPS) a valid prognostic score in patients with cirrhosis but also an advisor against TIPS?
    J Hepatol. 2021 Apr 26. pii: S0168-8278(21)00264.
    PubMed    


  124. VILLANUEVA C, Albillos A, Genesca J, Garcia-Pagan JC, et al
    Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis.
    J Hepatol. 2021 Apr 24. pii: S0168-8278(21)00257.
    PubMed     Abstract available


  125. GINES P
    Robert W Schrier, an influential observer from outside Hepatology (1936-2021).
    J Hepatol. 2021 Apr 20. pii: S0168-8278(21)00180.
    PubMed    


  126. TAPPER EB, Nikirk S, Parikh N, Zhao L, et al
    Falls are common, morbid, and predictable in patients with cirrhosis.
    J Hepatol. 2021 Apr 19. pii: S0168-8278(21)00247.
    PubMed     Abstract available


  127. OOI GJ, Meikle PJ, Huynh K, Earnest A, et al
    Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis.
    J Hepatol. 2021 Apr 19. pii: S0168-8278(21)00248.
    PubMed     Abstract available


  128. GOLSE N, Vibert E, Vignon-Clementel IE
    Comments on: "A step forward to predict the risk of post-hepatectomy portal hypertension".
    J Hepatol. 2021 Apr 15. pii: S0168-8278(21)00242.
    PubMed    


  129. SUNDARAM V
    Characterizing bacterial infections in acute-on-chronic liver failure among patients with cirrhosis from nonalcoholic steatohepatitis.
    J Hepatol. 2021 Apr 13. pii: S0168-8278(21)00240.
    PubMed    


  130. CRAMER T, Vaupel P
    Is tissue hypoxia the principle mechanism for immune evasion and malignant progression in Hepatocellular Carcinoma?
    J Hepatol. 2021 Apr 8. pii: S0168-8278(21)00228.
    PubMed    


  131. PRINZ P
    Comments on "fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis - A randomized controlled trial".
    J Hepatol. 2021 Apr 5. pii: S0168-8278(21)00225.
    PubMed    


  132. DESSEIN A
    Clinical utility of polygenic risk scores for predicting NAFLD disorders.
    J Hepatol. 2021;74:769-770.
    PubMed    


  133. COSTA D, Simbrunner B, Reiberger T
    Reply to: "Prognostic role of systemic inflammatory biomarkers in advanced chronic liver disease".
    J Hepatol. 2021;74:1000-1001.
    PubMed    


  134. HOBEIKA C, Fuks D
    Reply to: "Letter regarding Benchmark performance of laparoscopic left lateral sectionectomy and right hepatectomy in expert centers".
    J Hepatol. 2021;74:987-988.
    PubMed    


  135. HEGARTY R, Singh S, Bansal S, Fitzpatrick E, et al
    NAFLD to MAFLD in adults but the saga continues in children: an opportunity to advocate change.
    J Hepatol. 2021;74:991-992.
    PubMed    


  136. ESLAM M, Ratziu V, George J
    Yet more evidence that MAFLD is more than a name change.
    J Hepatol. 2021;74:977-979.
    PubMed    


  137. ESLAM M, George J
    MAFLD: A holistic view to redefining fatty liver disease.
    J Hepatol. 2021;74:983-985.
    PubMed    


  138. ESLAM M, George J
    MAFLD: A game changer redefining fatty liver disease for adults and children.
    J Hepatol. 2021;74:992-994.
    PubMed    


  139. AMPUERO J, Gallego-Duran R, Romero-Gomez M
    Reply to: "The predictive value of significant fibrosis for metabolic disturbances in patients with NAFLD".
    J Hepatol. 2021;74:971-972.
    PubMed    


  140. ZHENG KI, Sun DQ, Jin Y, Zhu PW, et al
    Clinical utility of the MAFLD definition.
    J Hepatol. 2021;74:989-991.
    PubMed    


  141. DEBNATH P, Rathi P
    Prognostic role of systemic inflammatory biomarkers in advanced chronic liver disease.
    J Hepatol. 2021;74:999-1000.
    PubMed    


  142. MORENO C, Sheron N, Tiniakos D, Lackner C, et al
    "Dual aetiology fatty liver disease": A recently proposed term associated with potential pitfalls.
    J Hepatol. 2021;74:979-982.
    PubMed    


  143. BAFFY G
    Is the name 'NAFLD' too big to fail? Let's keep it for 'nutrition-associated fatty liver disease'.
    J Hepatol. 2021;74:988.
    PubMed    


  144. XIA M, Zeng H, Wang S, Tang H, et al
    Insights into contribution of genetic variants towards the susceptibility of MAFLD revealed by the NMR-based lipoprotein profiling.
    J Hepatol. 2021;74:974-977.
    PubMed    


  145. LIU M, Sun L, Mao Y
    The predictive value of significant fibrosis for metabolic disturbances in patients with NAFLD.
    J Hepatol. 2021;74:970-971.
    PubMed    


  146. SINGH SP, Anirvan P, Reddy KR, Conjeevaram HS, et al
    Non-alcoholic fatty liver disease: Not time for an obituary just yet!
    J Hepatol. 2021;74:972-974.
    PubMed    


  147. PONIACHIK J, Roblero JP, Urzua A, Cattaneo M, et al
    A new definition for non-alcoholic fatty liver disease.
    J Hepatol. 2021;74:982-983.
    PubMed    


  148. RUSSOLILLO N, Aldrighetti L, Guglielmi A, Giuliante F, et al
    Correspondence on "Benchmark performance of laparoscopic left lateral sectionectomy and right hepatectomy in expert centers".
    J Hepatol. 2021;74:985-986.
    PubMed    


    March 2021
  149. POCH T, Krause J, Casar C, Liwinski T, et al
    Single-cell atlas of hepatic T cells reveals expansion of liver-resident naive-like CD4+ T cells in primary sclerosing cholangitis.
    J Hepatol. 2021 Mar 24. pii: S0168-8278(21)00219.
    PubMed     Abstract available


  150. MONTAGNESE S, Lauridsen M, Vilstrup H, Zarantonello L, et al
    A pilot study of Golexanolone, a new GABA-A receptor modulating steroid antagonist, in patients with covert hepatic encephalopathy.
    J Hepatol. 2021 Mar 24. pii: S0168-8278(21)00184.
    PubMed     Abstract available


  151. BASHO K, Bettinger D, Boettler T
    Reply to "IgG, a novel predictor for acute-on-chronic liver failure and survival in patients with decompensated cirrhosis?"
    J Hepatol. 2021 Mar 23. pii: S0168-8278(21)00187.
    PubMed    


  152. POSE E, Torrents A, Reverter E, Perez-Campuzano V, et al
    A notable proportion of liver transplant candidates with alcohol-related cirrhosis can be delisted because of clinical improvement.
    J Hepatol. 2021 Mar 18. pii: S0168-8278(21)00175.
    PubMed     Abstract available


  153. HARRISON SA, Gawrieh S, Roberts K, Lisanti CJ, et al
    Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort.
    J Hepatol. 2021 Mar 18. pii: S0168-8278(21)00176.
    PubMed     Abstract available


  154. AN YA, Chen S, Deng Y, Wang ZV, et al
    The mitochondrial dicarboxylate carrier prevents hepatic lipotoxicity by inhibiting white adipocyte lipolysis.
    J Hepatol. 2021 Mar 18. pii: S0168-8278(21)00174.
    PubMed     Abstract available


  155. PUTERA M, Teh KB, Kumar R, Wong YJ, et al
    Small esophageal varices in compensated cirrhosis patients: to treat or not to treat?
    J Hepatol. 2021 Mar 11. pii: S0168-8278(21)00167.
    PubMed    


  156. STOCKHOFF L, Schneider H, Tergast TL, Cornberg M, et al
    Freiburg index of post-TIPS survival (FIPS) a valid prognostic score in patients with cirrhosis but also an advisor against TIPS?
    J Hepatol. 2021 Mar 11. pii: S0168-8278(21)00168.
    PubMed    


  157. LIAO SH, Chen CL, Hsu CY, Chien KL, et al
    Long-term Effectiveness of Population-wide Multifaceted Interventions for Hepatocellular Carcinoma in Taiwan.
    J Hepatol. 2021 Mar 6. pii: S0168-8278(21)00163.
    PubMed     Abstract available


  158. GEIDL-FLUECK B, Hochuli M, Nemeth A, Eberl A, et al
    Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis: A randomized controlled trial.
    J Hepatol. 2021 Mar 5. pii: S0168-8278(21)00161.
    PubMed     Abstract available


  159. ANSTEE QM, Darlay R, Cockell S, Meroni M, et al
    Corrigendum to: "Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort" (J Hepatol [2020] 505-515).
    J Hepatol. 2021 Mar 4. pii: S0168-8278(21)00103.
    PubMed    


  160. JAMIALAHMADI O, Bianco C, Pelusi S, Romeo S, et al
    Population attributable risk of cirrhosis and hepatocellular carcinoma due to genetic predisposition to fatty liver disease.
    J Hepatol. 2021 Mar 4. pii: S0168-8278(21)00164.
    PubMed    


  161. WANG J, Liu D, Qi X
    A step forward to predict the risk of post-hepatectomy portal hypertension.
    J Hepatol. 2021 Mar 2. pii: S0168-8278(21)00159.
    PubMed    


  162. MEIJNIKMAN AS, Bruin S, Groen AK, Nieuwdorp M, et al
    Increased expression of key SARS-CoV-2 entry points in multiple tissues in individuals with NAFLD.
    J Hepatol. 2021;74:748-749.
    PubMed    


  163. MARJOT T, Moon AM, Cook JA, Abd-Elsalam S, et al
    Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study.
    J Hepatol. 2021;74:567-577.
    PubMed     Abstract available


  164. LUJAMBIO A, Maina F
    Turning up our understanding of liver cancer by a notch.
    J Hepatol. 2021;74:502-504.
    PubMed    


    February 2021
  165. SHAHINI E, Ahmed F
    Chronic fatigue should not be overlooked in primary biliary cholangitis.
    J Hepatol. 2021 Feb 25. pii: S0168-8278(21)00154.
    PubMed    


  166. KEIDING S, Frisch K, Hofmann AF
    Reply to: "Obeticholic acid and hepatic bile acids: Excellent study faulty conclusion".
    J Hepatol. 2021 Feb 20. pii: S0168-8278(21)00114.
    PubMed    


  167. MALLET V
    Intravenous ketamine and progressive cholangiopathy in Covid-19 patients.
    J Hepatol. 2021 Feb 19. pii: S0168-8278(21)00107.
    PubMed    


  168. HE Y, Feng D, Hwang S, Mackowiak B, et al
    Interleukin-20 exacerbates acute hepatitis and bacterial infection by downregulating IkappaBzeta target genes in hepatocytes.
    J Hepatol. 2021 Feb 18. pii: S0168-8278(21)00104.
    PubMed     Abstract available


  169. BARTOLI A, Gitto S, Sighinolfi P, Cursaro C, et al
    PRIMARY BILIARY CHOLANGITIS ASSOCIATED WITH SARS-COV2 INFECTION.
    J Hepatol. 2021 Feb 18. pii: S0168-8278(21)00106.
    PubMed    


  170. FABRIS L, Cadamuro M, Fouassier L
    Illuminate TWEAK/Fn14 pathway in intrahepatic cholangiocarcinoma: Another brick in the wall of tumor niche.
    J Hepatol. 2021 Feb 11. pii: S0168-8278(20)33892.
    PubMed    


  171. HARRISON SA, Bashir MR, Lee KJ, Shim-Lopez J, et al
    A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis.
    J Hepatol. 2021 Feb 10. pii: S0168-8278(21)00099.
    PubMed     Abstract available


  172. LIANG B, Zhou Y, Qian M, Xu M, et al
    TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis.
    J Hepatol. 2021 Feb 9. pii: S0168-8278(21)00095.
    PubMed     Abstract available


  173. LIEBE R, Esposito I, Bock HH, Dahl SV, et al
    Diagnosis and management of secondary causes of steatohepatitis.
    J Hepatol. 2021 Feb 9. pii: S0168-8278(21)00096.
    PubMed     Abstract available


  174. CORNBERG M, Buti M, Eberhardt CS, Grossi PA, et al
    EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients.
    J Hepatol. 2021 Feb 6. pii: S0168-8278(21)00081.
    PubMed     Abstract available


  175. TERGAST TL, Schultalbers M, Wedemeyer H, Cornberg M, et al
    IgG, a novel predictor for acute-on-chronic liver failure and survival in patients with decompensated cirrhosis?
    J Hepatol. 2021 Feb 3. pii: S0168-8278(21)00089.
    PubMed    


  176. GUPTA P, Soundararajan R, Patel A, Kumar-M P, et al
    Abbreviated MRI for hepatocellular carcinoma screening: A systematic review and meta-analysis.
    J Hepatol. 2021 Feb 3. pii: S0168-8278(21)00091.
    PubMed     Abstract available


  177. BEAUFRERE A, Calderaro J, Paradis V
    Combined hepatocellular-cholangiocarcinoma: An update.
    J Hepatol. 2021 Feb 2. pii: S0168-8278(21)00084.
    PubMed     Abstract available


  178. MUSHTAQ K, Khan MU, Iqbal F, Alsoub DH, et al
    NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression - The debate continues.
    J Hepatol. 2021;74:482-484.
    PubMed    


  179. JI D, Cheng G, Lau G
    Reply to: "NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression - The debate continues".
    J Hepatol. 2021;74:484-485.
    PubMed    


  180. RIPOLL C, Zipprich A
    Open or closed window: That is the question.
    J Hepatol. 2021;74:485-486.
    PubMed    


  181. ANAND A, Kumar R, Shalimar
    PREDICTing acute-on-chronic liver failure in patients with acute decompensation.
    J Hepatol. 2021;74:478-479.
    PubMed    


  182. HERNAEZ R, Kanwal F
    Reply to: "The role of the model for end-stage liver disease sodium score and joint models for 90-day mortality prediction in in patients with acute-on-chronic liver failure".
    J Hepatol. 2021;74:477.
    PubMed    


  183. GOUDSMIT BFJ, Tushuizen ME, Putter H, Braat AE, et al
    The role of the model for end-stage liver disease-sodium score and joint models for 90-day mortality prediction in patients with acute-on-chronic liver failure.
    J Hepatol. 2021;74:475-476.
    PubMed    


    January 2021
  184. SONG Q, Wang J, Griffiths A, Song Z, et al
    Reply to: "NNMT aggravates hepatic steatosis but alleviates liver injury in alcoholic liver disease" and "Two sides of NNMT in alcoholic and nonalcoholic fatty liver development".
    J Hepatol. 2021 Jan 30. pii: S0168-8278(21)00083.
    PubMed    


  185. GWAG T, Meng Z, Sui Y, Helsley RN, et al
    Erratum to: Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis [J Hepatol (2019); 70 (5): 930-940].
    J Hepatol. 2021 Jan 29. pii: S0168-8278(21)00003.
    PubMed    


  186. WU X, Poulsen KL, Sanz-Garcia C, Huang E, et al
    Erratum to: "MLKL-dependent signaling regulates autophagic flux in a murine model of non-alcoholic-associated fatty liver and steatohepatitis (J Hepatol 2020; 73: 616-627)".
    J Hepatol. 2021 Jan 29. pii: S0168-8278(21)00014.
    PubMed    


  187. JAVITT NB
    Obeticholic acid and hepatic bile acids: Excellent study faulty conclusion.
    J Hepatol. 2021 Jan 25. pii: S0168-8278(21)00044.
    PubMed    


  188. SAMUEL D
    Systemic inflammation and liver cirrhosis complications: driving or secondary event? How to square the circle?
    J Hepatol. 2021 Jan 18. pii: S0168-8278(21)00001.
    PubMed    


  189. LONG J, Bian J, Zhao H
    Polygenic risk score: a promising predictor for hepatocellular carcinoma in the population with nonalcoholic fatty liver disease.
    J Hepatol. 2021 Jan 18. pii: S0168-8278(21)00019.
    PubMed    


  190. JEPSEN P, West J
    We need stronger evidence for (or against) hepatocellular carcinoma surveillance.
    J Hepatol. 2021 Jan 16. pii: S0168-8278(21)00020.
    PubMed     Abstract available


  191. GOLDBERG D, Mantero A, Newcomb C, Delgado C, et al
    Predicting survival after liver transplantation in patients with hepatocellular carcinoma using the LiTES-HCC score.
    J Hepatol. 2021 Jan 13. pii: S0168-8278(21)00004.
    PubMed     Abstract available


  192. FAN R, Yin X, Hou J
    Reply to "External validation of aMAP risk score in Chronic hepatitis C genotype 4 patients with liver cirrhosis who achieved SVR following DAAs".
    J Hepatol. 2021 Jan 13. pii: S0168-8278(21)00011.
    PubMed    


  193. BURTON AR, Pallett LJ
    IL-2 leaves its mark in cirrhosis.
    J Hepatol. 2021 Jan 6. pii: S0168-8278(20)33833.
    PubMed    


  194. FORLANO R, Mullish BH, Maurice JB, Thursz MR, et al
    NAFLD: Time to apply quantitation in liver biopsies as endpoints in clinical trials.
    J Hepatol. 2021;74:241-242.
    PubMed    


  195. WU Y, Kumar R, Huang J, Wang M, et al
    FIB-4 cut-off should be re-evaluated in patients with metabolic associated fatty liver disease (MAFLD).
    J Hepatol. 2021;74:247-248.
    PubMed    


  196. NAYAGAM JS, Strautnieks S, Joshi D, Thompson RJ, et al
    Challenges in understanding the consequences of variants in ABCB4 gene.
    J Hepatol. 2021;74:242-243.
    PubMed    


  197. TSOCHATZIS EA, Srivastava A, Rosenberg W
    Reply to: "FIB-4 cut-off should be re-evaluated in patients with metabolic associated fatty liver disease (MAFLD)".
    J Hepatol. 2021;74:248-249.
    PubMed    


  198. SAVALE L, Sitbon O
    Reply to: "Management of portopulmonary hypertension: What is more important, PAH severity or liver disease severity?"
    J Hepatol. 2021;74:238-239.
    PubMed    


  199. KOLHE K, Tripathi DM, Kaur S
    Management of portopulmonary hypertension: What is more important, PAH severity or liver disease severity?
    J Hepatol. 2021;74:237-238.
    PubMed    


  200. STATTERMAYER AF, Ferenci P, Trauner M
    Reply to: "Challenges in understanding the consequences of variants in ABCB4 gene".
    J Hepatol. 2021;74:244-245.
    PubMed    


    December 2020
  201. FERRUSQUIA-ACOSTA J, Turco L, Hernandez-Gea V
    Reply to: "Underestimation of portal pressures by wedge hepatic venous pressures in patients with non-alcoholic steatohepatitis related cirrhosis- Possibilities and implications".
    J Hepatol. 2020 Dec 29. pii: S0168-8278(20)33837.
    PubMed    


  202. SHARMA S, Anand A, Saraya A
    Underestimation of portal pressures by wedge hepatic venous pressures in patients with non-alcoholic steatohepatitis related cirrhosis- Possibilities and implications.
    J Hepatol. 2020 Dec 22. pii: S0168-8278(20)33736.
    PubMed    


  203. WANG H, Chen J
    Reply to: "Prospective validation of Baveno VI criteria in virally supressed HBV cirrhosis - more evidence is needed".
    J Hepatol. 2020 Dec 19. pii: S0168-8278(20)33839.
    PubMed    


  204. SHARMA S, Agarwal S
    Prospective validation of Baveno VI criteria in virally supressed HBV cirrhosis - more evidence is needed.
    J Hepatol. 2020 Dec 19. pii: S0168-8278(20)33687.
    PubMed    


  205. LISMAN T, Luyendyk JP
    Response to "The Systemic Inflammation Hypothesis: Towards a New Paradigm of Acute Decompensation and Multiorgan Failure in Cirrhosis".
    J Hepatol. 2020 Dec 18. pii: S0168-8278(20)33890.
    PubMed    


  206. CALVARUSO V, Craxi A
    Reply to letters to the Editor on manuscript "Hepatic benefits of HCV cure". JHEPAT-D-20-01349R1.
    J Hepatol. 2020 Dec 17. pii: S0168-8278(20)33888.
    PubMed    


  207. SARKAR M, Grab J, Irani RA
    Reply to: "Intrahepatic cholestasis of pregnancy: An under recognised complication of maternal NAFLD?"
    J Hepatol. 2020 Dec 15. pii: S0168-8278(20)33806.
    PubMed    


  208. NINGARHARI M, Caruso S, Hirsch TZ, Bayard Q, et al
    Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target.
    J Hepatol. 2020 Dec 15. pii: S0168-8278(20)33846.
    PubMed     Abstract available


  209. AVANCENA ALV, Miller N, Uttal SE, Hutton DW, et al
    Cost-effectiveness of alcohol use treatments in patients with alcohol-related cirrhosis.
    J Hepatol. 2020 Dec 13. pii: S0168-8278(20)33841.
    PubMed     Abstract available


  210. MARINO Z, Darnell A, Lens S, Sapena V, et al
    Corrigendum to "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules" [J Hepatol (2019) 874-884].
    J Hepatol. 2020 Dec 11. pii: S0168-8278(20)33773.
    PubMed    


  211. PHILLIPS J, Senaratne S
    Intrahepatic cholestasis of pregnancy: An under recognised complication of maternal NAFLD?
    J Hepatol. 2020 Dec 11. pii: S0168-8278(20)33694.
    PubMed    


  212. BRESSON-HADNI S, Montange D, Richou C, Brumpt E, et al
    Tobacco, cannabis, and liquorice: Hidden players altering albendazole metabolism in patients with hepatic alveolar echinococcosis.
    J Hepatol. 2020 Dec 10. pii: S0168-8278(20)33749.
    PubMed    


  213. ARROYO V, Angeli P, Moreau R, Jalan R, et al
    The Systemic Inflammation Hypothesis: Towards a New Paradigm of Acute Decompensation and Multiorgan Failure in Cirrhosis.
    J Hepatol. 2020 Dec 7. pii: S0168-8278(20)33836.
    PubMed     Abstract available


  214. BOYER-DIAZ Z, Aristu-Zabalza P, Andres-Rozas M, Robert C, et al
    Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease.
    J Hepatol. 2020 Dec 2. pii: S0168-8278(20)33832.
    PubMed     Abstract available


  215. TREBICKA J, Fernandez J, Arroyo V
    Reply to: Correspondence on 'The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology'.
    J Hepatol. 2020 Dec 2. pii: S0168-8278(20)33765.
    PubMed    


  216. WEIL D, Thevenot T, Saas P, Di Martino V, et al
    Relevance of platelet-derived microvesicles in cirrhosis: The debate remains open.
    J Hepatol. 2020 Dec 2. pii: S0168-8278(20)33745.
    PubMed    


  217. BAUMERT TF
    The Nobel Prize in Medicine 2020 for the Discovery of Hepatitis C Virus: Transforming Hepatology.
    J Hepatol. 2020;73:1303-1305.
    PubMed    


  218. VASAVAN T, Deepak S, Jayawardane IA, Lucchini M, et al
    Fetal cardiac dysfunction in intrahepatic cholestasis of pregnancy is associated with elevated serum bile acid concentrations.
    J Hepatol. 2020 Dec 1. pii: S0168-8278(20)33825.
    PubMed     Abstract available


  219. DIGGS LP, Ruf B, Ma C, Heinrich B, et al
    CD40-mediated immune cell activation enhances response to anti-PD1 in murine intrahepatic cholangiocarcinoma.
    J Hepatol. 2020 Dec 1. pii: S0168-8278(20)33824.
    PubMed     Abstract available


  220. MARTINEZ-CHANTAR ML, Foti M
    NFATc4: New hub in NASH development.
    J Hepatol. 2020;73:1313-1315.
    PubMed    


  221. TANWAR S, Srivastava A, Rosenberg W
    Errors in modeling misrepresent the utility of the enhanced liver fibrosis test in the management of non-alcoholic fatty liver disease.
    J Hepatol. 2020;73:1580-1581.
    PubMed    


  222. HERNAEZ R, Liu Y, Kanwal F
    Reply to: "Model for end-stage liver disease-sodium in acute-on-chronic liver failure".
    J Hepatol. 2020;73:1579-1580.
    PubMed    


  223. MOSCA A, Panera N, Maggiore G, Alisi A, et al
    From pregnant women to infants: Non-alcoholic fatty liver disease is a poor inheritance.
    J Hepatol. 2020;73:1590-1592.
    PubMed    


  224. GOH BKP
    Letter regarding "Benchmark performance of laparoscopic left lateral sectionectomy and right hepatectomy in expert centers".
    J Hepatol. 2020;73:1576.
    PubMed    


  225. HOBEIKA C, Fuks D
    Reply to: 'Letter regarding "Benchmark performance of laparoscopic left lateral sectionectomy and right hepatectomy in expert centers"'.
    J Hepatol. 2020;73:1577-1578.
    PubMed    


  226. VALI Y, Anstee QM, Bossuyt PM
    Reply to: "Errors in modeling misrepresent the utility of the enhanced liver fibrosis test in the management of non-alcoholic fatty liver disease".
    J Hepatol. 2020;73:1582-1583.
    PubMed    


  227. MAK LY, Yuen MF, Seto WK
    Letter regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement".
    J Hepatol. 2020;73:1573-1574.
    PubMed    


  228. MANKA P, Canbay A, Bechmann LP
    Model for end-stage liver disease-sodium in acute-on-chronic liver failure.
    J Hepatol. 2020;73:1578-1579.
    PubMed    


  229. ESLAM M, George J
    Reply to: correspondence regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement": Bringing evidence to the NAFLD-MAFLD debate.
    J Hepatol. 2020;73:1575.
    PubMed    


  230. RATZIU V, Rinella M, Beuers U, Loomba R, et al
    The times they are a-changin' (for NAFLD as well).
    J Hepatol. 2020;73:1307-1309.
    PubMed    


  231. JALAN R, Arroyo V
    Organ allocation for patients with acute-on-chronic liver failure: Time to look beyond MELD-sodium?
    J Hepatol. 2020;73:1316-1318.
    PubMed    


    November 2020
  232. KUPRIYANOVA Y, Zaharia OP, Bobrov P, Karusheva Y, et al
    Early changes in hepatic energy metabolism and lipid content in recent-onset type 1 and 2 diabetes mellitus.
    J Hepatol. 2020 Nov 28. pii: S0168-8278(20)33817.
    PubMed     Abstract available


  233. BIANCO C, Jamialahmadi O, Pelusi S, Baselli G, et al
    Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores.
    J Hepatol. 2020 Nov 25. pii: S0168-8278(20)33811.
    PubMed     Abstract available


  234. SU F, Weiss NS, Beste LA, Moon AM, et al
    Screening is associated with a lower risk of hepatocellular carcinoma-related mortality in patients with chronic hepatitis B.
    J Hepatol. 2020 Nov 24. pii: S0168-8278(20)33807.
    PubMed     Abstract available


  235. DING Q, Ma Y, Lai S, Dou X, et al
    NNMT aggravates hepatic steatosis, but alleviates liver injury in alcoholic liver disease.
    J Hepatol. 2020 Nov 24. pii: S0168-8278(20)33812.
    PubMed    


  236. KELLUM JA, Nadim MK
    Acute kidney disease and cirrhosis.
    J Hepatol. 2020 Nov 23. pii: S0168-8278(20)33756.
    PubMed    


  237. KRASSENBURG LAP, Maan R, Ramji A, Manns MP, et al
    Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
    J Hepatol. 2020 Nov 23. pii: S0168-8278(20)33805.
    PubMed     Abstract available


  238. TREBICKA J, Fernandez J, Papp M, Caraceni P, et al
    PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis.
    J Hepatol. 2020 Nov 20. pii: S0168-8278(20)33772.
    PubMed     Abstract available


  239. CHEN H, Cai J, Wang J, Qiu Y, et al
    Targeting Nestin(+) hepatic stellate cells ameliorates liver fibrosis by facilitating TbetaRI degradation.
    J Hepatol. 2020 Nov 17. pii: S0168-8278(20)33769.
    PubMed     Abstract available


  240. HUANG YH, Zhang CZ, Huang QS, Yeong J, et al
    Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma.
    J Hepatol. 2020 Nov 16. pii: S0168-8278(20)33763.
    PubMed     Abstract available


  241. GOLSE N, Joly F, Combari P, Lewin M, et al
    Predicting the risk of post-hepatectomy portal hypertension using a digital twin: a clinical proof of concept.
    J Hepatol. 2020 Nov 16. pii: S0168-8278(20)33761.
    PubMed     Abstract available


  242. ARECHEDERRA M, Bazai SK, Abdouni A, Sequera C, et al
    ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma.
    J Hepatol. 2020 Nov 13. pii: S0168-8278(20)33758.
    PubMed     Abstract available


  243. MEHTA N, Dodge JL, Roberts JP, Yao FY, et al
    A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival.
    J Hepatol. 2020 Nov 11. pii: S0168-8278(20)33750.
    PubMed     Abstract available


  244. KUCUKOGLU O, Sowa JP, Mazzolini GD, Syn WK, et al
    Hepatokines and adipokines in NASH-related hepatocellular carcinoma.
    J Hepatol. 2020 Nov 5. pii: S0168-8278(20)33746.
    PubMed     Abstract available


  245. ZANETTO A, Simioni P, Russo FP
    Hepatic benefits of HCV cure: don't forget coagulation!
    J Hepatol. 2020 Nov 5. pii: S0168-8278(20)33747.
    PubMed    


  246. ANTOINE DJ, Jenkins RE, Dear JW, Williams DP, et al
    Retraction notice to "Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity": J Hepatol 56(2012)1070-1079.
    J Hepatol. 2020;73:1297.
    PubMed    


  247. JOTHIMANI D, Venugopal R, Abedin MF, Kaliamoorthy I, et al
    COVID-19 and the liver.
    J Hepatol. 2020;73:1231-1240.
    PubMed     Abstract available


  248. MEHTANI R, Roy A, Verma N, Premkumar M, et al
    Beta-blockers in refractory ascites - is it truly the end of the road?
    J Hepatol. 2020;73:1290-1291.
    PubMed    


  249. TELLEZ L, Ibanez-Samaniego L, Banares R, Albillos A, et al
    Reply to: "Beta-blockers in refractory ascites - is it truly the end of the road?"
    J Hepatol. 2020;73:1291-1292.
    PubMed    


  250. UNFRIED JP, Fortes P
    SMIM30, a tiny protein with a big role in liver cancer.
    J Hepatol. 2020;73:1010-1012.
    PubMed    


  251. HUANG J, Kumar R, Wang M, Zhu Y, et al
    MAFLD criteria overlooks a number of patients with severe steatosis: Is it clinically relevant?
    J Hepatol. 2020;73:1265-1267.
    PubMed    


  252. ESLAM M, George J
    Reply to: Correspondence on "A new definition for metabolic associated fatty liver disease: an international expert consensus statement": MAFLD: Moving from a concept to practice.
    J Hepatol. 2020;73:1268-1269.
    PubMed    


  253. VAN HEES S, Muyindike W, Erem G, Ocama P, et al
    Challenges associated with the roll-out of HCC surveillance in sub-Saharan Africa - the case of Uganda.
    J Hepatol. 2020;73:1271-1273.
    PubMed    


  254. SINGAL AG, Lampertico P, Nahon P
    Reply to: "Challenges associated with the roll-out of HCC surveillance in sub-Saharan Africa - the case of Uganda".
    J Hepatol. 2020;73:1273-1274.
    PubMed    


    October 2020
  255. WANG J, Wang Y, Chu Y, Li Z, et al
    Tumor-derived adenosine promotes macrophage proliferation in human hepatocellular carcinoma.
    J Hepatol. 2020 Oct 30. pii: S0168-8278(20)33739.
    PubMed     Abstract available


  256. CHAN SL
    Hyperprogression in hepatocellular carcinoma: Illusion or reality?
    J Hepatol. 2020 Oct 24. pii: S0168-8278(20)33669.
    PubMed    


  257. TRAMPERT DC, van de Graaf SFJ, Jongejan A, Oude Elferink RPJ, et al
    Hepatobiliary acid-base homeostasis: Insights from analogous secretory epithelia.
    J Hepatol. 2020 Oct 24. pii: S0168-8278(20)33690.
    PubMed     Abstract available


  258. MOHS A, Otto T, Schneider KM, Peltzer M, et al
    Hepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis.
    J Hepatol. 2020 Oct 24. pii: S0168-8278(20)33695.
    PubMed     Abstract available


  259. BASHO K, Zoldan K, Schultheiss M, Bettinger D, et al
    IL-2 contributes to cirrhosis-associated immune dysfunction by impairing follicular T helper cells in advanced cirrhosis.
    J Hepatol. 2020 Oct 23. pii: S0168-8278(20)33692.
    PubMed     Abstract available


  260. SHIHA G, Mikhail N, Soliman R
    External validation of aMAP risk score in Chronic hepatitis C genotype 4 patients with liver cirrhosis who achieved SVR following DAAs.
    J Hepatol. 2020 Oct 23. pii: S0168-8278(20)33688.
    PubMed    


  261. DEPAIRE M, Larrue H, Rudler M, Nault JC, et al
    Futility criteria for preemptive TIPS in patients with cirrhosis and variceal bleeding are still missing in most severe patients!
    J Hepatol. 2020 Oct 23. pii: S0168-8278(20)33689.
    PubMed    


  262. MOGA L, Laroyenne A, Larrue H, Bureau C, et al
    Patients with NAFLD do not have severe portal hypertension in the absence of cirrhosis.
    J Hepatol. 2020 Oct 23. pii: S0168-8278(20)33691.
    PubMed    


  263. ROSE CF, Amodio P, Bajaj JS, Dhiman RK, et al
    Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy.
    J Hepatol. 2020 Oct 21. pii: S0168-8278(20)30466.
    PubMed     Abstract available


  264. FERRUSQUIA-ACOSTA J, Bassegoda O, Turco L, Reverter E, et al
    Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis.
    J Hepatol. 2020 Oct 14. pii: S0168-8278(20)33683.
    PubMed     Abstract available


  265. CARBONE M, Ronca V, Invernizzi P
    Reply to: "A spotlight on natural killer cells in primary biliary cholangitis".
    J Hepatol. 2020 Oct 14. pii: S0168-8278(20)33663.
    PubMed    


  266. HYDES T, Khakoo SI
    A spotlight on natural killer cells in primary biliary cholangitis.
    J Hepatol. 2020 Oct 14. pii: S0168-8278(20)33595.
    PubMed    


  267. CAI SY, Yu D, Soroka CJ, Wang J, et al
    Hepatic NFAT signaling regulates the expression of inflammatory cytokines in cholestasis.
    J Hepatol. 2020 Oct 8. pii: S0168-8278(20)33680.
    PubMed     Abstract available


  268. WANG H, Wen B, Chang X, Wu Q, et al
    Baveno VI criteria and spleen stiffness measurement rule out high-risk varices in virally suppressed HBV-related cirrhosis.
    J Hepatol. 2020 Oct 8. pii: S0168-8278(20)33678.
    PubMed     Abstract available


  269. MORIKAWA R, Nakamoto N, Amiya T, Chu PS, et al
    Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis.
    J Hepatol. 2020 Oct 7. pii: S0168-8278(20)33677.
    PubMed     Abstract available


  270. FRENETTE C, Kayali Z, Mena E, Mantry PS, et al
    Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis.
    J Hepatol. 2020 Oct 7. pii: S0168-8278(20)33673.
    PubMed     Abstract available


  271. ZHU C, Ho YJ, Salomao MA, Dapito DH, et al
    Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features.
    J Hepatol. 2020 Oct 7. pii: S0168-8278(20)33676.
    PubMed     Abstract available


  272. KIM TH, Koh YH, Kim BH, Kim MJ, et al
    Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: a randomized phase trial.
    J Hepatol. 2020 Oct 5. pii: S0168-8278(20)33670.
    PubMed     Abstract available


  273. LIU C, Zha Z, Zhou C, Chen Y, et al
    Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma.
    J Hepatol. 2020 Oct 5. pii: S0168-8278(20)33674.
    PubMed     Abstract available


  274. FONDEVILA MF, Mercado-Gomez M, Rodriguez A, Gonzalez-Rellan MJ, et al
    Obese patients with NASH have increased hepatic expression of SARS-CoV-2 critical entry points.
    J Hepatol. 2020 Oct 5. pii: S0168-8278(20)33671.
    PubMed    


  275. MAGAZ M, Alvarez-Larran A, Colomer D, Lopez M, et al
    Reply to: Correspondence on "Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis".
    J Hepatol. 2020 Oct 2. pii: S0168-8278(20)33621.
    PubMed    


  276. WANG Y, Lu F, Zhao J
    Reply to: Correspondence relating to "SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19".
    J Hepatol. 2020;73:996-998.
    PubMed    


  277. MEHAL WZ
    From mice to humans: Unravelling the genetic levers of NASH.
    J Hepatol. 2020;73:749-751.
    PubMed    


  278. O'BRIEN A, Karvellas CJ
    Acute-on-chronic liver failure: The challenge of PREDICTing who and when.
    J Hepatol. 2020;73:755-756.
    PubMed    


  279. HUO TI, Ho SY, Ko CC
    Stereotactic body radiation therapy vs. radiofrequency ablation for HCC: More questions than answers.
    J Hepatol. 2020;73:972-973.
    PubMed    


  280. SCHWARZKOPF KM, Eberle L, Uschner FE, Klein S, et al
    Interleukin-22 in acute-on-chronic liver failure: A matter of ineffective levels, receptor dysregulation or defective signalling?
    J Hepatol. 2020;73:980-982.
    PubMed    


  281. TREBICKA J, Gu W, Garcia-Pagan JC, Bosch J, et al
    Reply to: "Pre-emptive TIPS for acute variceal bleeding in acute-on-chronic liver failure: Is there enough evidence for a routine recommendation?": pTIPS for variceal bleeding in ACLF patients: when and why?
    J Hepatol. 2020;73:977-979.
    PubMed    


  282. XIANG X, Hwang S, Gao B
    Reply to: "Interleukin-22 in acute-on-chronic liver failure: A matter of ineffective levels, receptor dysregulation or defective signalling?": The search for an optimal mouse model.
    J Hepatol. 2020;73:982-984.
    PubMed    


  283. ELHENCE A, Kumar R, Shalimar
    Pre-emptive TIPS for acute variceal bleeding in acute-on-chronic liver failure: Is there enough evidence for a routine recommendation?
    J Hepatol. 2020;73:976-977.
    PubMed    


  284. KIM N, Seong J
    Reply to: "Stereotactic body radiation therapy vs. radiofrequency ablation for HCC: More questions than answers".
    J Hepatol. 2020;73:973-974.
    PubMed    


    September 2020
  285. WEN Z, Feng Y, Yan X
    Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
    J Hepatol. 2020 Sep 29. pii: S0168-8278(20)30491.
    PubMed    


  286. GRONBAEK H, Gantzel RH, Laursen TL, Kazankov K, et al
    Macrophage markers and innate immunity in cirrhosis.
    J Hepatol. 2020 Sep 26. pii: S0168-8278(20)30486.
    PubMed    


  287. PAPATHEODORIDIS G, Sypsa V, Lampertico P
    Reply to: "Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B".
    J Hepatol. 2020 Sep 25. pii: S0168-8278(20)33615.
    PubMed    


  288. SCHUMACHER N, Yan K, Gandrass M, Muller M, et al
    Cell-autonomous hepatocyte-specific GP130 signalling is sufficient to trigger a robust innate immune response in mice.
    J Hepatol. 2020 Sep 25. pii: S0168-8278(20)33664.
    PubMed     Abstract available


  289. TREMBLAY D, Mascarenhas J, Schiano T, Naymagon L, et al
    Comment on "Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis".
    J Hepatol. 2020 Sep 24. pii: S0168-8278(20)30531.
    PubMed    


  290. ZHENG KI, Liu C, Li J, Zhao L, et al
    Validation of Baveno VI and expanded Baveno VI criteria to identify high-risk varices in patients with MAFLD-related compensated cirrhosis.
    J Hepatol. 2020 Sep 21. pii: S0168-8278(20)30447.
    PubMed    


  291. ARGIRION I, Mahale P, Pfeiffer RM, Koshiol J, et al
    Cirrhotic controls in a pooled analysis of hepatitis D and hepatocellular carcinoma.
    J Hepatol. 2020 Sep 19. pii: S0168-8278(20)30465.
    PubMed    


  292. PARISINOS CA, Wilman HR, Thomas EL, Kelly M, et al
    Corrigendum to: "Genome-wide and Mendelian randomisation studies of liver MRI yield insights into the pathogenesis of steatohepatitis" [J Hepatol (2020) 241-251].
    J Hepatol. 2020 Sep 17. pii: S0168-8278(20)33603.
    PubMed    


  293. SECKLER F, Doussot A, Colpart P, Turco C, et al
    Preoperative immunotherapy for resectable hepatocellular carcinoma: Toward a paradigm shift?
    J Hepatol. 2020 Sep 17. pii: S0168-8278(20)30366.
    PubMed    


  294. SCHATTENBERG JM, Straub BK
    On the value and limitations of liver histology in assessing non-alcoholic steatohepatitis.
    J Hepatol. 2020 Sep 12. pii: S0168-8278(20)30475.
    PubMed    


  295. ALFAIATE D, Clement S, Goossens N, Negro F, et al
    Reply to: "Cirrhotic controls in a pooled analysis of hepatitis D and hepatocellular carcinoma".
    J Hepatol. 2020 Sep 12. pii: S0168-8278(20)30543.
    PubMed    


  296. KIM N, Cheng J, Jung I, Liang J, et al
    Corrigendum to: "Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma" [J Hepatol (2020) 121-129].
    J Hepatol. 2020 Sep 10. pii: S0168-8278(20)33602.
    PubMed    


  297. TONON M, Rosi S, Gambino CG, Piano S, et al
    Natural history of acute kidney disease in patients with cirrhosis.
    J Hepatol. 2020 Sep 9. pii: S0168-8278(20)33612.
    PubMed     Abstract available


  298. CHAN LK, Wai-Hung Ho D, Kam CS, Yung-Tuen Chiu E, et al
    RSK2-inactivating mutations potentiate MAPK signaling and support cholesterol metabolism in hepatocellular carcinoma.
    J Hepatol. 2020 Sep 9. pii: S0168-8278(20)33610.
    PubMed     Abstract available


  299. SAVALE L, Guimas M, Ebstein N, Fertin M, et al
    Corrigendum to: "Portopulmonary hypertension in the current era of pulmonary hypertension management" [J Hepatol (2020);73:130-139].
    J Hepatol. 2020 Sep 7. pii: S0168-8278(20)33591.
    PubMed    


  300. FABRIS L, Andersen JB, Fouassier L
    Intrahepatic cholangiocarcinoma: A single-cell resolution unraveling the complexity of the tumor microenvironment.
    J Hepatol. 2020 Sep 5. pii: S0168-8278(20)30471.
    PubMed    


  301. MERLI M
    Nutrition in cirrhosis: Dos and Don'ts.
    J Hepatol. 2020 Sep 2. pii: S0168-8278(20)30474.
    PubMed    


  302. SERPER M, Shaked A, Olthoff KM, Hoteit M, et al
    A local response to COVID-19 for advanced liver disease: Current model of care, challenges and opportunities.
    J Hepatol. 2020;73:708-709.
    PubMed    


  303. VALENTI L, Jamialahmadi O, Romeo S
    Lack of genetic evidence that fatty liver disease predisposes to COVID-19.
    J Hepatol. 2020;73:709-711.
    PubMed    


  304. DI GIORGIO A, Nicastro E, Speziani C, De Giorgio M, et al
    Health status of patients with autoimmune liver disease during SARS-CoV-2 outbreak in northern Italy.
    J Hepatol. 2020;73:702-705.
    PubMed    


  305. JI D, Xu J, Qin E, Zhang D, et al
    Reply to: 'No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease'.
    J Hepatol. 2020;73:718-719.
    PubMed    


  306. BIQUARD L, Valla D, Rautou PE
    No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease.
    J Hepatol. 2020;73:717-718.
    PubMed    


  307. RICKE J, Sangro B, Malfertheiner P, Seidensticker M, et al
    Reply to: "Toxicity and dosimetry in SORAMIC study".
    J Hepatol. 2020;73:735-736.
    PubMed    


  308. REINDERS M, Braat A, Lam M
    Toxicity and dosimetry in SORAMIC study.
    J Hepatol. 2020;73:734-735.
    PubMed    


  309. DYSON JK, Jones DEJ
    UDCA prophylaxis for post-transplant PBC recurrence prevention: Time to change practice.
    J Hepatol. 2020;73:499-501.
    PubMed    


  310. PAISANT A, Vilgrain V, Aube C
    Reply to: "Selection of MRI contrast agent and diagnostic criteria for HCC to maximize the advantages of contrast agents".
    J Hepatol. 2020;73:716-717.
    PubMed    


  311. CHOI SH, Kim SY, Lim YS
    Selection of MRI contrast agent and diagnostic criteria for HCC to maximize the advantages of contrast agents.
    J Hepatol. 2020;73:714-715.
    PubMed    


  312. ILIC I, Milovanovic T
    The risk-benefit assessment of liver biopsy in times of non-invasive screening for liver fibrosis.
    J Hepatol. 2020;73:701-702.
    PubMed    


  313. GUIU B
    Stereotactic body radiation therapy vs. radiofrequency ablation in HCC: comparing noncomparable data.
    J Hepatol. 2020;73:727-728.
    PubMed    


  314. JI D, Zhang D, Lau G
    Reply to: 'NAFLD or comorbidities, that is the question'.
    J Hepatol. 2020;73:724-725.
    PubMed    


  315. PONZIANI FR, Gasbarrini A, Pompili M
    NAFLD or comorbidities, that is the question.
    J Hepatol. 2020;73:723.
    PubMed    


    August 2020
  316. CHARETTE JH, Burak KW, Coffin CS, Congly SE, et al
    Evaluating the role of transient elastography post chronic hepatitis C treatment to predict hepatocellular carcinoma.
    J Hepatol. 2020 Aug 31. pii: S0168-8278(20)30458.
    PubMed    


  317. GENESCA J
    Reply to: "Evaluating the role of transient elastography post chronic hepatitis C treatment to predict hepatocellular carcinoma".
    J Hepatol. 2020 Aug 24. pii: S0168-8278(20)30484.
    PubMed    


  318. CARACENI P, Tufoni M, Zaccherini G, Riggio O, et al
    On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites.
    J Hepatol. 2020 Aug 24. pii: S0168-8278(20)33551.
    PubMed     Abstract available


  319. XU Z, Li H, Tian S, Wu J, et al
    Blood biomarkers for the diagnosis of hepatic steatosis in metabolic dysfunction-associated fatty liver disease.
    J Hepatol. 2020 Aug 21. pii: S0168-8278(20)30371.
    PubMed    


  320. SERENARI M, Ravaioli F, Cucchetti A, Kim SU, et al
    Reply to: "Response to A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma".
    J Hepatol. 2020 Aug 21. pii: S0168-8278(20)30442.
    PubMed    


  321. FAN L, Lai R, Ma N, Dong Y, et al
    miR-552-3p modulates transcriptional activities of FXR and LXR to ameliorate hepatic glycolipid metabolism disorder.
    J Hepatol. 2020 Aug 17. pii: S0168-8278(20)30541.
    PubMed     Abstract available


  322. RHEE H, Cho ES, Nahm JH, Jang M, et al
    Gadoxetic acid-enhanced MRI of macrotrabecular-massive hepatocellular carcinoma and its prognostic implications.
    J Hepatol. 2020 Aug 17. pii: S0168-8278(20)30544.
    PubMed     Abstract available


  323. LINE PD, Dueland S
    Liver transplantation for secondary liver tumors: the difficult balance between survival and recurrence.
    J Hepatol. 2020 Aug 17. pii: S0168-8278(20)30539.
    PubMed    


  324. KIM CG, Kim C, Yoon SE, Kim KH, et al
    Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma.
    J Hepatol. 2020 Aug 15. pii: S0168-8278(20)30540.
    PubMed     Abstract available


  325. MANNING C, Alam SM
    Response to "A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma".
    J Hepatol. 2020 Aug 14. pii: S0168-8278(20)30380.
    PubMed    


  326. SOLA E, Pose E, Campion D, Piano S, et al
    ENDPOINTS AND DESIGN OF CLINICAL TRIALS IN PATIENTS WITH DECOMPENSATED CIRRHOSIS: POSITION PAPER OF THE LIVERHOPE CONSORTIUM.
    J Hepatol. 2020 Aug 14. pii: S0168-8278(20)30536.
    PubMed     Abstract available


  327. CALVARUSO V, Craxi A
    Hepatic benefits of HCV cure.
    J Hepatol. 2020 Aug 7. pii: S0168-8278(20)30530.
    PubMed     Abstract available


  328. IAVARONE M, D'Ambrosio R, Lampertico P
    Authors' reply on HIGH RATES OF 30-DAY MORTALITY IN PATIENTS WITH CIRRHOSIS AND COVID-19.
    J Hepatol. 2020 Aug 6. pii: S0168-8278(20)30524.
    PubMed    


  329. CALVARUSO V, Bruix J
    Towards personalized screening for hepatocellular carcinoma: still not there.
    J Hepatol. 2020 Aug 5. pii: S0168-8278(20)30405.
    PubMed    


  330. GAUL S, Leszczynska A, Alegre F, Kaufmann B, et al
    Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis.
    J Hepatol. 2020 Aug 4. pii: S0168-8278(20)30522.
    PubMed     Abstract available


  331. JI D, Qin E, Xu J, Zhang D, et al
    Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study.
    J Hepatol. 2020;73:451-453.
    PubMed    


  332. MERAT SJ, Bru C, van de Berg D, Molenkamp R, et al
    Erratum to: 'Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance' (J Hepatol 2019; 71(1): 14-24).
    J Hepatol. 2020 Aug 1. pii: S0168-8278(20)30455.
    PubMed    


  333. PRAKTIKNJO M, Torner J, Simon-Talero M, Gu W, et al
    Reply to: "Definition of SPSS: we need to speak the same language": Computer-assisted image processing for better quantification.
    J Hepatol. 2020;73:464-465.
    PubMed    


  334. NICOARA-FARCAU O, Wang X, Luo X
    Definition of SPSS: we need to speak the same language.
    J Hepatol. 2020;73:463-464.
    PubMed    


    July 2020
  335. KOMOLL RM, Hu Q, Olarewaju O, von Dohlen L, et al
    MicroRNA-342-3p is a potent tumour suppressor in hepatocellular carcinoma.
    J Hepatol. 2020 Jul 30. pii: S0168-8278(20)30492.
    PubMed     Abstract available


  336. LUO YD, Fang L, Yu HQ, Zhang J, et al
    p53 haploinsufficiency and increased mTOR signaling define a subset of aggressive hepatocellular carcinoma.
    J Hepatol. 2020 Jul 29. pii: S0168-8278(20)30489.
    PubMed     Abstract available


  337. KJAERGAARD K, Frisch K, Sorensen M, Munk OL, et al
    Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis.
    J Hepatol. 2020 Jul 24. pii: S0168-8278(20)30481.
    PubMed     Abstract available


  338. DU M, Wang X, Yuan L, Liu B, et al
    Targeting NFATc4 attenuates non-alcoholic steatohepatitis in mice.
    J Hepatol. 2020 Jul 24. pii: S0168-8278(20)30482.
    PubMed     Abstract available


  339. SANGRO B, Melero I, Wadhawan S, Finn RS, et al
    Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma.
    J Hepatol. 2020 Jul 22. pii: S0168-8278(20)30479.
    PubMed     Abstract available


  340. FAN R, Papatheodoridis G, Sun J, Innes H, et al
    aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis.
    J Hepatol. 2020 Jul 21. pii: S0168-8278(20)30478.
    PubMed     Abstract available


  341. LOHSE AW, Sebode M, Jorgensen MH, Ytting H, et al
    Second-line and Third-line therapy for Autoimmune Hepatitis A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group.
    J Hepatol. 2020 Jul 21. pii: S0168-8278(20)30470.
    PubMed     Abstract available


  342. SERENARI M, Ravaioli F, Cucchetti A, Kim SU, et al
    Reply to: "Liver stiffness: A novel predictor of postoperative complications in patients with hepatocellular carcinoma".
    J Hepatol. 2020 Jul 20. pii: S0168-8278(20)30388.
    PubMed    


  343. XU G, Xiao Y, Jin B, Sang X, et al
    Liver stiffness: A novel predictor of postoperative complications in patients with hepatocellular carcinoma.
    J Hepatol. 2020 Jul 20. pii: S0168-8278(20)30343.
    PubMed    


  344. TAJES SR, Pocurull A, Castillo J, Casanova G, et al
    Hepatitis C-related cirrhosis will be a marginal cause of hospital admissions in the near future.
    J Hepatol. 2020 Jul 19. pii: S0168-8278(20)30472.
    PubMed     Abstract available


  345. SONG Y, An O, Ren X, Man Chan TH, et al
    RNA editing mediates the functional switch of COPA in a novel mechanism of hepatocarcinogenesis.
    J Hepatol. 2020 Jul 18. pii: S0168-8278(20)30476.
    PubMed     Abstract available


  346. ZHANG X, Fan L, Wu J, Xu H, et al
    Erratum to: "Macrophage p38 alpha promotes nutritional steatohepatitis through M1 polarization (J Hepatol 2019; 71(1):163-174)".
    J Hepatol. 2020 Jul 17. pii: S0168-8278(20)30390.
    PubMed    


  347. VERNA EC, Akushevich L, Vainorius M, Fried MW, et al
    Reply to: "HCV treatment in cirrhotic patients: Should we use a different approach for patients with a liver transplant perspective?"
    J Hepatol. 2020 Jul 15. pii: S0168-8278(20)30386.
    PubMed    


  348. MAGAZ M, Alvarez-Larran A, Colomer D, Lopez-Guerra M, et al
    Next generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis.
    J Hepatol. 2020 Jul 14. pii: S0168-8278(20)30456.
    PubMed     Abstract available


  349. SABOO K, Shamsaddini A, Iyer MV, Hu C, et al
    Sex is associated with differences in gut microbial composition and function in hepatic encephalopathy.
    J Hepatol. 2020 Jul 14. pii: S0168-8278(20)30457.
    PubMed     Abstract available


  350. MCPHAIL MJW, Coen M
    Metabolomics to discriminate between acute decompensation and acute-on-chronic liver failure in cirrhosis.
    J Hepatol. 2020 Jul 14. pii: S0168-8278(20)30183.
    PubMed    


  351. TREBICKA J, Fernandez J, Papp M, Caraceni P, et al
    The PREDICT study uncovers three clinical courses in acutely decompensated cirrhosis with distinct pathophysiology (120/120).
    J Hepatol. 2020 Jul 10. pii: S0168-8278(20)30384.
    PubMed     Abstract available


  352. AMPUERO J, Aller R, Gallego-Duran R, Crespo J, et al
    Erratum to: "Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17-25).
    J Hepatol. 2020 Jul 9. pii: S0168-8278(20)30389.
    PubMed    


  353. MOREAU R, Aguilar F, Arroyo V
    Reply to: "Metabolomics to discriminate between acute decompensation and acute-on-chronic liver failure in cirrhosis".
    J Hepatol. 2020 Jul 8. pii: S0168-8278(20)30340.
    PubMed    


  354. MEUNIER L, Pageaux GP, Coilly A
    HCV treatment in cirrhotic patients: Should we use a different approach for patients with a liver transplant perspective?
    J Hepatol. 2020 Jul 8. pii: S0168-8278(20)30345.
    PubMed    


  355. DEEB M, Karlsen TH, Hirschfield GM
    The 6 C's of Primary Sclerosing Cholangitis.
    J Hepatol. 2020 Jul 7. pii: S0168-8278(20)30436.
    PubMed    


  356. RINELLA ME, Noureddin M
    STELLAR 3 and STELLAR 4: Lessons from the fall of Icarus.
    J Hepatol. 2020;73:9-11.
    PubMed    


  357. LAZARUS JV, Cortez-Pinto H, Anstee QM
    Reply to: "Caveats for the implementation of global strategies against non-alcoholic fatty liver disease".
    J Hepatol. 2020;73:221-222.
    PubMed    


  358. SHAH S, Dhami-Shah H, Kamble S, Shukla A, et al
    FIB-4 cut-off of 1.3 may be inappropriate in a primary care referral pathway for patients with non-alcoholic fatty liver disease.
    J Hepatol. 2020;73:216-217.
    PubMed    


  359. LEUNG M, Piao C, Sarkar S
    NAFLD referral patterns in a large US academic center.
    J Hepatol. 2020;73:218-219.
    PubMed    


  360. TSOCHATZIS EA, Srivastava A, Rosenberg W
    Reply to: "FIB-4 cut off of 1.3 may be inappropriate in a primary care referral pathway for patients with non-alcoholic fatty liver disease".
    J Hepatol. 2020;73:217-218.
    PubMed    


  361. MENDEZ-SANCHEZ N, Valencia-Rodriguez A
    Caveats for the implementation of global strategies against non-alcoholic fatty liver disease.
    J Hepatol. 2020;73:220.
    PubMed    


  362. ZOU ZY, Fan JG
    Incidence of chronic kidney disease in patients with non-alcoholic fatty liver disease.
    J Hepatol. 2020;73:214-216.
    PubMed    


    June 2020
  363. AUDUREAU E, Carrat F, Layese R, Cagnot C, et al
    Personalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV status.
    J Hepatol. 2020 Jun 29. pii: S0168-8278(20)30394.
    PubMed     Abstract available


  364. DONG P, Wang X, Liu L, Tang W, et al
    Dampened VEPH1 activates mTORC1 signaling by weakening the TSC1/TSC2 association in hepatocellular carcinoma.
    J Hepatol. 2020 Jun 28. pii: S0168-8278(20)30400.
    PubMed     Abstract available


  365. RUART M, Chavarria L, Camprecios G, Suarez-Herrera N, et al
    Corrigendum to: "Impaired endothelial autophagy promotes liver fibrosis by aggravating the oxidative stress response during acute liver injury" [J Hepatol (2019) 458-469].
    J Hepatol. 2020 Jun 27. pii: S0168-8278(20)30354.
    PubMed    


  366. LAMPL S, Janas MK, Donakonda S, Brugger M, et al
    Reduced mitochondrial resilience enables non-canonical induction of apoptosis after TNF receptor signaling in virus-infected hepatocytes.
    J Hepatol. 2020 Jun 26. pii: S0168-8278(20)30398.
    PubMed     Abstract available


  367. HAMON A, Piquet-Pellorce C, Dimanche-Boitrel MT, Samson M, et al
    Intrahepatocytic necroptosis is dispensable for hepatocyte death in murine immune-mediated hepatitis.
    J Hepatol. 2020 Jun 23. pii: S0168-8278(20)30308.
    PubMed    


  368. FRAGA M, Moradpour D, Artru F, Romailler E, et al
    Hepatocellular Type II Fibrinogen Inclusions in a Patient with Severe COVID-19 and Hepatitis.
    J Hepatol. 2020 Jun 22. pii: S0168-8278(20)30393.
    PubMed    


  369. BASSEGODA O, Sola E, Gines P
    Reply to: "Transition of AKI to CKD in cirrhosis - effect of baseline eGFR and unanswered questions".
    J Hepatol. 2020 Jun 21. pii: S0168-8278(20)30287.
    PubMed    


  370. GAO F, Huang ZM
    The impact of COVID-19 on the clinical outcome of patients with cirrhosis deserves more attention and research.
    J Hepatol. 2020 Jun 20. pii: S0168-8278(20)30397.
    PubMed    


  371. MEDHAT MA, El Kassas M
    Letter regarding [High rates of 30-day mortality in patients with cirrhosis and COVID-19].
    J Hepatol. 2020 Jun 20. pii: S0168-8278(20)30396.
    PubMed    


  372. KUMAR R, Kerbert AJC, Sheikh MF, Roth N, et al
    Determinants of mortality in patients with cirrhosis and uncontrolled variceal bleeding.
    J Hepatol. 2020 Jun 16. pii: S0168-8278(20)30381.
    PubMed     Abstract available


  373. BABU RO, Hang Lui VC, Chen Y, Wan Yiu RS, et al
    Beta-amyloid deposition around hepatic bile ducts is a novel pathobiological and diagnostic feature of biliary atresia.
    J Hepatol. 2020 Jun 16. pii: S0168-8278(20)30383.
    PubMed     Abstract available


  374. COLNOT S, Lechel A
    Maternal obesity: A severe risk factor in hepatocarcinogenesis?
    J Hepatol. 2020 Jun 16. pii: S0168-8278(20)30385.
    PubMed    


  375. PAPATHEODORIDIS GV, Dalekos GN, Idilman R, Sypsa V, et al
    Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
    J Hepatol. 2020 Jun 15. pii: S0168-8278(20)30382.
    PubMed     Abstract available


  376. SINGH I, De A, Singh V
    Transition of AKI to CKD in cirrhosis - effect of baseline eGFR and unanswered questions.
    J Hepatol. 2020 Jun 12. pii: S0168-8278(20)30184.
    PubMed    


  377. RAI RP, Liu Y, Iyer SS, Liu S, et al
    Blocking integrin alpha4beta7-mediated CD4 T cell recruitment to the intestine and liver protects mice from western diet-induced non-alcoholic steatohepatitis.
    J Hepatol. 2020 Jun 12. pii: S0168-8278(20)30375.
    PubMed     Abstract available


  378. LENS S, Baiges A, Alvarado E, LLop E, et al
    Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension.
    J Hepatol. 2020 Jun 11. pii: S0168-8278(20)30368.
    PubMed     Abstract available


  379. IAVARONE M, D'Ambrosio R, Soria A, Triolo M, et al
    High rates of 30-day mortality in patients with cirrhosis and COVID-19.
    J Hepatol. 2020 Jun 8. pii: S0168-8278(20)30365.
    PubMed     Abstract available


  380. JEPSEN P, Kraglund F, West J, Villadsen GE, et al
    Risk of hepatocellular carcinoma in Danish outpatients with alcohol-related cirrhosis.
    J Hepatol. 2020 Jun 5. pii: S0168-8278(20)30363.
    PubMed     Abstract available


  381. ZHANG M, Yang H, Wan L, Wang Z, et al
    Single cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma.
    J Hepatol. 2020 Jun 4. pii: S0168-8278(20)30360.
    PubMed     Abstract available


  382. SHIHA G
    External validation of non-invasive predictors of hepatocellular carcinoma in patients with HCV-related advanced chronic liver disease after oral antivirals.
    J Hepatol. 2020 Jun 3. pii: S0168-8278(20)30196.
    PubMed    


  383. MAK LY, Wan-Hin Hui R, Fung J, Liu F, et al
    Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B.
    J Hepatol. 2020 Jun 3. pii: S0168-8278(20)30361.
    PubMed     Abstract available


  384. MAK LY, Ka-Ho Wong D, Pollicino T, Raimondo G, et al
    Occult hepatitis B infection and hepatocellular carcinoma: epidemiology, virology, hepatocarcinogenesis and clinical significance.
    J Hepatol. 2020 Jun 3. pii: S0168-8278(20)30357.
    PubMed     Abstract available


  385. GENESCA J
    Reply to: "Hepatocellular carcinoma surveillance after hepatitis C virus eradication: Is liver stiffness measurement more useful than laboratory fibrosis markers?" and "External validation of noninvasive predictors of hepatocellular carcinoma in patie
    J Hepatol. 2020 Jun 1. pii: S0168-8278(20)30237.
    PubMed    


  386. NABATCHIKOVA E, Abdurakhmanov D, Rozina T, Nikulkina E, et al
    Hepatocellular carcinoma surveillance after hepatitis C virus eradication: Is liver stiffness measurement more useful than laboratory fibrosis markers?
    J Hepatol. 2020 Jun 1. pii: S0168-8278(20)30197.
    PubMed    


  387. EDELINE J, Garin E
    Streamlining TARE or personalizing SIRT? Different philosophies to treat different HCCs with Yttrium-90....
    J Hepatol. 2020;72:1046-1048.
    PubMed    


  388. HARMS MH, van Buuren HR, van der Meer AJ
    Reply to: "Switching vs. add-on strategy in PBC treatment: Lessons from UDCA and bezafibrate experience".
    J Hepatol. 2020;72:1211-1212.
    PubMed    


  389. CORPECHOT C, Rousseau A, Chazouilleres O
    Switching vs. add-on strategy in PBC treatment: Lessons from UDCA and bezafibrate experience.
    J Hepatol. 2020;72:1210-1211.
    PubMed    


  390. KHORUTS A, Bajaj JS
    Reply to: " 'You know my name, but not my story' - Deciding on an accurate nomenclature for faecal microbiota transplantation": Intestinal microbiota transplantation: Naming a new paradigm.
    J Hepatol. 2020;72:1213-1214.
    PubMed    


  391. PHILIPS CA, Ahamed R, Rajesh S, Augustine P, et al
    'You know my name, but not my story' - Deciding on an accurate nomenclature for faecal microbiota transplantation.
    J Hepatol. 2020;72:1212-1213.
    PubMed    


    May 2020
  392. DE SMET V, Verhulst S, van Grunsven LA
    Single cell RNA sequencing analysis did not predict hepatocyte infection by SARS-CoV-2.
    J Hepatol. 2020 May 27. pii: S0168-8278(20)30349.
    PubMed    


  393. LUUKKONEN PK, Juuti A, Sammalkorpi H, Penttila AK, et al
    MARC1 variant rs2642438 increases hepatic phosphatidylcholines and decreases severity of non-alcoholic fatty liver disease in humans.
    J Hepatol. 2020 May 26. pii: S0168-8278(20)30234.
    PubMed    


  394. KIM N, Seong J
    Reply to: "Can sorafenib use influence outcome when comparing stereotactic body radiation therapy with radiofrequency ablation in patients with hepatocellular carcinoma?"
    J Hepatol. 2020 May 25. pii: S0168-8278(20)30229.
    PubMed    


  395. CHEW CA, Iyer SG, Chieh Kow AW, Madhavan K, et al
    An international multicentre study of protocols for liver transplantation during a pandemic: A case for quadripartite equipoise.
    J Hepatol. 2020 May 23. pii: S0168-8278(20)30342.
    PubMed     Abstract available


  396. TELLEZ L, Ibanez-Samaniego L, Perez Del Villar C, Yotti R, et al
    Non-selective beta-blockers impair global circulatory homeostasis and renal function in cirrhotic patients with refractory ascites.
    J Hepatol. 2020 May 21. pii: S0168-8278(20)30303.
    PubMed     Abstract available


  397. MOON AM, Webb GJ, Aloman C, Armstrong MJ, et al
    High Mortality Rates for SARS-CoV-2 Infection in Patients with Pre-existing Chronic Liver Disease and Cirrhosis: Preliminary Results from an International Registry.
    J Hepatol. 2020 May 20. pii: S0168-8278(20)30305.
    PubMed    


  398. CHAN HL, Wong VW, Yip TC, Wong GL, et al
    Reply to: "Hepatocellular carcinoma risk stratification in HBV cirrhosis: Time to turn the page".
    J Hepatol. 2020 May 15. pii: S0168-8278(20)30273.
    PubMed    


  399. RIOU J, Canivet CM, Boursier J
    Reply to: "Accurate diagnosis of NAFLD-related hepatic fibrosis with non-invasive methods: A comment for moving forward".
    J Hepatol. 2020 May 15. pii: S0168-8278(20)30233.
    PubMed    


  400. LUCIFORA J, Michelet M, Rivoire M, Protzer U, et al
    Two-dimensional-cultures of primary human hepatocytes allow efficient HBV infection: Old tricks still work!
    J Hepatol. 2020 May 15. pii: S0168-8278(20)30204.
    PubMed    


  401. SONNEVELD MJ, Brouwer WP, de Man RA
    Hepatocellular carcinoma risk stratification in HBV cirrhosis: Time to turn the page?
    J Hepatol. 2020 May 15. pii: S0168-8278(20)30231.
    PubMed    


  402. GULFO J, Rotondo F, de Leon CGA, Cornide-Petronio ME, et al
    FGF15 improves outcomes after brain dead donor liver transplantation with steatotic and non-steatotic grafts in rats.
    J Hepatol. 2020 May 15. pii: S0168-8278(20)30299.
    PubMed     Abstract available


  403. LI W
    Accurate diagnosis of NAFLD-related hepatic fibrosis with non-invasive methods: A comment for moving forward.
    J Hepatol. 2020 May 13. pii: S0168-8278(20)30179.
    PubMed    


  404. KUMAR A
    Can sorafenib use influence outcome when comparing stereotactic body radiation therapy with radiofrequency ablation in patients with hepatocellular carcinoma?
    J Hepatol. 2020 May 11. pii: S0168-8278(20)30175.
    PubMed    


  405. PENG ZP, Jiang ZZ, Guo HF, Zhou MM, et al
    Glycolytic activation of monocytes regulates the accumulation and function of neutrophils in human hepatocellular carcinoma.
    J Hepatol. 2020 May 11. pii: S0168-8278(20)30296.
    PubMed     Abstract available


  406. WANG Y, Liu S, Liu H, Li W, et al
    SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19.
    J Hepatol. 2020 May 10. pii: S0168-8278(20)30294.
    PubMed     Abstract available


  407. WANG S, Friedman SL
    Hepatic fibrosis: A convergent response to liver injury that is reversible.
    J Hepatol. 2020 May 8. pii: S0168-8278(20)30170.
    PubMed    


  408. GAO J, Wei B, de Assuncao TM, Liu Z, et al
    Hepatic stellate cell autophagy inhibits extracellular vesicle release to attenuate liver fibrosis.
    J Hepatol. 2020 May 7. pii: S0168-8278(20)30290.
    PubMed     Abstract available


  409. DESAI AP, Knapp SM, Orman ES, Ghabril MS, et al
    Changing epidemiology and outcomes of acute kidney injury in hospitalized patients with cirrhosis - a US population-based study.
    J Hepatol. 2020 May 6. pii: S0168-8278(20)30289.
    PubMed     Abstract available


  410. MEYER T
    Stereotactic body radiotherapy for hepatocellular carcinoma - still searching for a role.
    J Hepatol. 2020 May 6. pii: S0168-8278(20)30232.
    PubMed    


  411. DAI Z, Ott M, Sharma AD
    Equal opportunity offer for all hepatocytes.
    J Hepatol. 2020 May 6. pii: S0168-8278(20)30200.
    PubMed    


  412. SCHWERBEL K, Kamitz A, Krahmer N, Hallahan N, et al
    Immunity-related GTPase induces lipophagy to prevent excess hepatic lipid accumulation.
    J Hepatol. 2020 May 3. pii: S0168-8278(20)30275.
    PubMed     Abstract available


  413. BATES J, Vijayakumar A, Ghoshal S, Marchand B, et al
    Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
    J Hepatol. 2020 May 3. pii: S0168-8278(20)30281.
    PubMed     Abstract available


  414. STATTERMAYER AF, Halilbasic E, Wrba F, Ferenci P, et al
    Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults.
    J Hepatol. 2020 May 3. pii: S0168-8278(20)30280.
    PubMed     Abstract available


  415. ABE H, Schuppan D
    beta-arrestin: Dr Jekyll and Mr Hyde in NASH and fibrosis.
    J Hepatol. 2020;72:813-815.
    PubMed    


    April 2020
  416. SERENARI M, Han KH, Ravaioli F, Kim SU, et al
    A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma.
    J Hepatol. 2020 Apr 30. pii: S0168-8278(20)30276.
    PubMed     Abstract available


  417. LEFERE S, Puengel T, Hundertmark J, Penners C, et al
    Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages.
    J Hepatol. 2020 Apr 29. pii: S0168-8278(20)30269.
    PubMed     Abstract available


  418. HIRSCH TZ, Negulescu A, Gupta B, Caruso S, et al
    Corrigendum to: "BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA" [J Hepatol (2020) 1-13].
    J Hepatol. 2020 Apr 29. pii: S0168-8278(20)30214.
    PubMed    


  419. MAZUMDER NR, Celaj S, Atiemo K, Daud A, et al
    Liver-related mortality is similar among men and women with cirrhosis.
    J Hepatol. 2020 Apr 25. pii: S0168-8278(20)30235.
    PubMed     Abstract available


  420. FORREST E
    Alcohol-related liver disease results in significant long-term mortality irrespective of the presence of steatohepatitis.
    J Hepatol. 2020 Apr 20. pii: S0168-8278(20)30117.
    PubMed    


  421. DEGRE D, Stauber RE, Deltenre P, Lackner C, et al
    Reply to: "Alcohol-related liver disease results in significant long-term mortality irrespective of the presence of steatohepatitis".
    J Hepatol. 2020 Apr 20. pii: S0168-8278(20)30199.
    PubMed    


  422. OKINA Y, Sato-Matsubara M, Matsubara T, Daikoku A, et al
    TGF-beta-driven reduction of cytoglobin leads to oxidative DNA damage in stellate cells during non-alcoholic steatohepatitis.
    J Hepatol. 2020 Apr 17. pii: S0168-8278(20)30228.
    PubMed     Abstract available


  423. TAPPER EB, Asrani SK
    COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care.
    J Hepatol. 2020 Apr 13. pii: S0168-8278(20)30217.
    PubMed     Abstract available


  424. TAPIAS EA, Ardevol A, Garcia-Guix M, Montanes R, et al
    Short-term hemodynamic effects of beta-blockers influence survival of patients with decompensated cirrhosis.
    J Hepatol. 2020 Apr 13. pii: S0168-8278(20)30211.
    PubMed     Abstract available


  425. ANSTEE QM, Darlay R, Cockell S, Meroni M, et al
    Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically-characterised cohort.
    J Hepatol. 2020 Apr 13. pii: S0168-8278(20)30213.
    PubMed     Abstract available


  426. LOPEZ-VICARIO C, Checa A, Urdangarin A, Aguilar F, et al
    Targeted lipidomics reveals extensive changes in circulating lipid mediators in patients with acutely decompensated cirrhosis.
    J Hepatol. 2020 Apr 12. pii: S0168-8278(20)30208.
    PubMed     Abstract available


  427. CORPECHOT C, Chazouilleres O, Belnou P, Montano-Loza AJ, et al
    Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis.
    J Hepatol. 2020 Apr 7. pii: S0168-8278(20)30205.
    PubMed     Abstract available


  428. PARISINOS CA, Wilman HR, Thomas EL, Kelly M, et al
    Genome-wide and Mendelian randomisation studies of liver MRI yield insights into the pathogenesis of steatohepatitis.
    J Hepatol. 2020 Apr 2. pii: S0168-8278(20)30194.
    PubMed     Abstract available


  429. CHOUDHARY NS, Saraf N, Saigal S, Soin AS, et al
    Non-enhanced magnetic resonance as a surveillance tool for hepatocellular carcinoma: Many unresolved issues.
    J Hepatol. 2020 Apr 2. pii: S0168-8278(20)30016.
    PubMed    


  430. LEE HA, Kim BK, Kim SU
    Clinical relevance of dynamic risk assessment for developing hepatocellular carcinoma during prolonged antiviral therapy.
    J Hepatol. 2020 Apr 1. pii: S0168-8278(20)30121.
    PubMed    


  431. GANNE-CARRIE N, Piscaglia F
    Non-enhanced MRI surveillance for HCC: A new tool for all, none or selected patients at risk?
    J Hepatol. 2020;72:607-609.
    PubMed    


  432. ENGELMANN C, Mehta G, Tacke F
    Regeneration in acute-on-chronic liver failure - the phantom lost its camouflage.
    J Hepatol. 2020;72:610-612.
    PubMed    


    March 2020
  433. VERNA EC, Morelli G, Terrault NA, Lok AS, et al
    DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.
    J Hepatol. 2020 Mar 31. pii: S0168-8278(20)30193.
    PubMed     Abstract available


  434. SANGIOVANNI A, Alimenti E, Gattai R, Filomia R, et al
    Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis.
    J Hepatol. 2020 Mar 31. pii: S0168-8278(20)30192.
    PubMed     Abstract available


  435. LAI JC, Dodge JL, Kappus MR, Dunn MA, et al
    Changes in frailty are associated with waitlist mortality in patients with cirrhosis.
    J Hepatol. 2020 Mar 30. pii: S0168-8278(20)30191.
    PubMed     Abstract available


  436. BERNSMEIER C, van der Merwe S, Perianin A
    The innate immune cells in cirrhosis.
    J Hepatol. 2020 Mar 30. pii: S0168-8278(20)30189.
    PubMed     Abstract available


  437. CARRILLO-REIXACH J, Torrens L, Simon-Coma M, Royo L, et al
    Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications.
    J Hepatol. 2020 Mar 30. pii: S0168-8278(20)30187.
    PubMed     Abstract available


  438. NEWSOME PN, Palmer M, Freilich B, Sheikh MY, et al
    Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study.
    J Hepatol. 2020 Mar 28. pii: S0168-8278(20)30186.
    PubMed     Abstract available


  439. PAPATHEODORIDIS GV, Lampertico P
    Reply to: "Clinical relevance of dynamic risk assessment for developing hepatocellular carcinoma during prolonged antiviral therapy".
    J Hepatol. 2020 Mar 27. pii: S0168-8278(20)30173.
    PubMed    


  440. PARK HJ, Jang HY, Kim SY
    Reply to: "Non-enhanced magnetic resonance as a surveillance tool for hepatocellular carcinoma: Many unresolved issues".
    J Hepatol. 2020 Mar 26. pii: S0168-8278(20)30162.
    PubMed    


  441. KHAN SA, Clements O, Kim JU, Eliahoo J, et al
    Reply to: 'Letter regarding [Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis]'.
    J Hepatol. 2020 Mar 23. pii: S0168-8278(20)30128.
    PubMed    


  442. CUCCHETTI A, Serenari M, Sposito C, Di Sandro S, et al
    Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant.
    J Hepatol. 2020 Mar 19. pii: S0168-8278(20)30177.
    PubMed     Abstract available


  443. KOWDLEY KV, Vuppalanchi R, Levy C, Floreani A, et al
    A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.
    J Hepatol. 2020 Mar 9. pii: S0168-8278(20)30160.
    PubMed     Abstract available


  444. HARRISON SA, Wai-Sun Wong V, Okanoue T, Bzowej N, et al
    Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials.
    J Hepatol. 2020 Mar 5. pii: S0168-8278(20)30126.
    PubMed     Abstract available


  445. SAVALE L, Guimas M, Ebstein N, Fertin M, et al
    Portopulmonary hypertension in the current era of pulmonary hypertension management.
    J Hepatol. 2020 Mar 4. pii: S0168-8278(20)30119.
    PubMed     Abstract available


  446. WONG VW
    Predicting NASH response with liver fat: Are we back to square one?
    J Hepatol. 2020;72:386-388.
    PubMed    


    February 2020
  447. ARFIANTI A, Pok S, Barn V, Haigh WG, et al
    Exercise retards hepatocarcinogenesis in obese mice independently of weight control.
    J Hepatol. 2020 Feb 20. pii: S0168-8278(20)30104.
    PubMed     Abstract available


  448. VAN WESSEL DBE, Thompson RJ, Gonzales E, Jankowska I, et al
    Genotype correlates with the natural history of severe bile salt export pump deficiency.
    J Hepatol. 2020 Feb 19. pii: S0168-8278(20)30105.
    PubMed     Abstract available


  449. MULLER M, Bird TG, Nault JC
    The landscape of gene mutations in cirrhosis and hepatocellular carcinoma.
    J Hepatol. 2020 Feb 7. pii: S0168-8278(20)30060.
    PubMed     Abstract available


    January 2020
  450. BAJAJ JS, Khoruts A
    Microbiota changes and Intestinal Microbiota Transplantation in Liver Diseases and Cirrhosis.
    J Hepatol. 2020 Jan 28. pii: S0168-8278(20)30058.
    PubMed     Abstract available


  451. PRAKTIKNJO M, Simon-Talero M, Romer J, Roccarina D, et al
    Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis.
    J Hepatol. 2020 Jan 15. pii: S0168-8278(20)30012.
    PubMed     Abstract available


  452. BASSEGODA O, Huelin P, Ariza X, Sole C, et al
    DEVELOPMENT OF CHRONIC KIDNEY DISEASE AFTER ACUTE KIDNEY INJURY IN PATIENTS WITH CIRRHOSIS IS COMMON AND IMPAIRS CLINICAL OUTCOMES.
    J Hepatol. 2020 Jan 14. pii: S0168-8278(20)30011.
    PubMed     Abstract available


    December 2019
  453. PAISANT A, Vilgrain V, Riou J, Oberti F, et al
    Comparison of extracellular and hepatobiliary MR contrast agents for the diagnosis of small HCCs.
    J Hepatol. 2019 Dec 20. pii: S0168-8278(19)30725.
    PubMed     Abstract available


  454. GARCIA-TSAO G, Bosch J, Kayali Z, Harrison SA, et al
    Randomized Placebo-Controlled Trial of Emricasan in Non-alcoholic Steatohepatitis (NASH) Cirrhosis with Severe Portal Hypertension.
    J Hepatol. 2019 Dec 20. pii: S0168-8278(19)30724.
    PubMed     Abstract available


  455. SHE S, Wu X, Zheng D, Pei X, et al
    PSMP/MSMP promotes hepatic fibrosis through CCR2 and represents a novel therapeutic target.
    J Hepatol. 2019 Dec 5. pii: S0168-8278(19)30654.
    PubMed     Abstract available


    November 2019
  456. CHIEW AL, James LP, Isbister GK, Pickering JW, et al
    Early Acetaminophen-Protein Adducts Predict Hepatotoxicity Following Overdose.
    J Hepatol. 2019 Nov 21. pii: S0168-8278(19)30677.
    PubMed     Abstract available


  457. HE X, Wang Y, Fan X, Lei N, et al
    A schistosome miRNA promotes host hepatic fibrosis by targeting transforming growth factor beta receptor III.
    J Hepatol. 2019 Nov 15. pii: S0168-8278(19)30674.
    PubMed     Abstract available


    October 2019
  458. SUNDARAM V, Kogachi S, Wong RJ, Karvellas CJ, et al
    Effect of the clinical course of acute on chronic liver failure prior to liver transplantation on post-transplant survival.
    J Hepatol. 2019 Oct 25. pii: S0168-8278(19)30640.
    PubMed     Abstract available


  459. GIANNELLI V, Roux O, Laouenan C, Manchon P, et al
    Impact of cardiac function, refractory ascites and beta blockers on the outcome of patients with cirrhosis listed for liver transplantation.
    J Hepatol. 2019 Oct 14. pii: S0168-8278(19)30603.
    PubMed     Abstract available


  460. BRIL F, Barb D, Lomonaco R, Lai J, et al
    Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis.
    J Hepatol. 2019 Oct 4. pii: S0168-8278(19)30584.
    PubMed     Abstract available


    August 2019
  461. BHANGUI P, Lim C, Levesque E, Salloum C, et al
    Novel Classification of Nonmalignant Portal Vein Thrombosis: A guide to Surgical Decision Making during Liver Transplantation.
    J Hepatol. 2019 Aug 20. pii: S0168-8278(19)30479.
    PubMed     Abstract available


    June 2019
  462. AL-DURY S, Wahlstrom A, Panzitt K, Thorell A, et al
    Obeticholic acid may increase the risk of gallstone formation in susceptible patients.
    J Hepatol. 2019 Jun 26. pii: S0168-8278(19)30383.
    PubMed     Abstract available


  463. WANG J, Wang H, Peters M, Ding N, et al
    Loss of Fbxw7 synergizes with activated AKT signaling to promote c-Myc dependent cholangiocarcinogenesis.
    J Hepatol. 2019 Jun 10. pii: S0168-8278(19)30342.
    PubMed     Abstract available


  464. RAVICHANDRAN G, Neumann K, Berkhout LK, Weidemann S, et al
    Interferon-gamma-dependent immune responses contribute to the pathogenesis of sclerosing cholangitis in mice.
    J Hepatol. 2019 Jun 4. pii: S0168-8278(19)30309.
    PubMed     Abstract available


    May 2019
  465. DE TYMOWSKI C, Depret F, Soussi S, Nabila M, et al
    Contributing factors and outcomes of burn-associated cholestasis.
    J Hepatol. 2019 May 29. pii: S0168-8278(19)30292.
    PubMed     Abstract available


    April 2019
  466. HARMS MH, van Buuren HR, Corpechot C, Thorburn D, et al
    Ursodeoxycholic Acid Therapy and Liver Transplant-free Survival in Patients with Primary Biliary Cholangitis.
    J Hepatol. 2019 Apr 10. pii: S0168-8278(19)30228.
    PubMed     Abstract available


    March 2019
  467. TSUNODA T, Kakinuma S, Miyoshi M, Kamiya A, et al
    Loss of Fibrocystin Promotes Interleukin-8-Dependent Proliferation and CTGF Production of Biliary Epithelium.
    J Hepatol. 2019 Mar 15. pii: S0168-8278(19)30146.
    PubMed     Abstract available


  468. JAIN V, Burford C, Alexander EC, Sutton H, et al
    Prognostic markers at adolescence in patients Biliary Atresia for liver transplantation in adulthood.
    J Hepatol. 2019 Mar 12. pii: S0168-8278(19)30143.
    PubMed     Abstract available


    December 2018
  469. ICHAI P, Laurent-Bellue A, Camus C, Moreau D, et al
    Liver transplantation in patients with liver failure related to exertional heatstroke.
    J Hepatol. 2018 Dec 3. pii: S0168-8278(18)32575.
    PubMed     Abstract available


    November 2018
  470. HIRSCHFIELD GM, Chazouilleres O, Drenth JP, Thorburn D, et al
    Effect of NGM282, a FGF19 analogue, in Primary Sclerosing Cholangitis: a Multicentre, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.
    J Hepatol. 2018 Nov 8. pii: S0168-8278(18)32519.
    PubMed     Abstract available


    July 2018
  471. LAUTERIO A, Moioli MC, Di Sandro S, Travi G, et al
    HIV-positive to HIV-positive liver transplantation: To be continued.
    J Hepatol. 2018 Jul 23. pii: S0168-8278(18)32180.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: